{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:55:03Z","timestamp":1791244503243,"version":"4.1.0"},"reference-count":395,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08584-2","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:53:04Z","timestamp":1783565584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Regulated cell death plasticity in cancer: thresholds, reversibility, and therapeutic failure"],"prefix":"10.1186","volume":"24","author":[{"given":"Tooba","family":"Jawwad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadaf Khursheed","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Surendranath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Jeelani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammira S.","family":"Al-Shabeeb Akil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Al Menhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz A.","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-2421","authenticated-orcid":false,"given":"Sameer","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"13","key":"8584_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/cells13131083","volume":"13","author":"M D\u2019Amico","year":"2024","unstructured":"D\u2019Amico M, De Amicis F. Challenges of regulated cell death: implications for therapy resistance in cancer. Cells. 2024;13(13):1083. https:\/\/doi.org\/10.3390\/cells13131083.","journal-title":"Cells"},{"issue":"2","key":"8584_CR2","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41418-022-01082-0","volume":"30","author":"FJ Bock","year":"2023","unstructured":"Bock FJ, Riley JS. When cell death goes wrong: inflammatory outcomes of failed apoptosis and mitotic cell death. Cell Death Differ. 2023;30(2):293\u2013303. https:\/\/doi.org\/10.1038\/s41418-022-01082-0.","journal-title":"Cell Death Differ"},{"key":"8584_CR3","doi-asserted-by":"crossref","unstructured":"Bora J, Banerjee S, Barman I, Rustagi S, Mishra R, Malik S. Apoptosis defects in cancer and its therapeutic implications. In: Promising cancer therapeutic drug targets: recent advancements. Bentham Science Publishers; 2025.","DOI":"10.2174\/9789815238570125010015"},{"issue":"10","key":"8584_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1113205.","journal-title":"N Engl J Med"},{"issue":"4","key":"8584_CR5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018.","journal-title":"Cell"},{"issue":"7467","key":"8584_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature12625","volume":"501","author":"RA Burrell","year":"2013","unstructured":"Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338\u201345. https:\/\/doi.org\/10.1038\/nature12625.","journal-title":"Nature"},{"issue":"9","key":"8584_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrm2952","volume":"11","author":"SWG Tait","year":"2010","unstructured":"Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11(9):621\u201332. https:\/\/doi.org\/10.1038\/nrm2952.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"8584_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrc.2015.17","volume":"16","author":"ARD Delbridge","year":"2016","unstructured":"Delbridge ARD, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99\u2013109. https:\/\/doi.org\/10.1038\/nrc.2015.17.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"8584_CR9","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.molcel.2015.01.018","volume":"57","author":"G Ichim","year":"2015","unstructured":"Ichim G, Lopez J, Ahmed SU, Muthalagu N, Giampazolias E, Delgado ME, et al. Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death. Mol Cell. 2015;57(5):860\u201372. https:\/\/doi.org\/10.1016\/j.molcel.2015.01.018.","journal-title":"Mol Cell"},{"issue":"5","key":"8584_CR10","doi-asserted-by":"publisher","first-page":"803","DOI":"10.15252\/msb.20145584","volume":"11","author":"J Roux","year":"2015","unstructured":"Roux J, Hafner M, Bandara S, Sims JJ, Hudson H, Chai D, et al. Fractional killing arises from cell-to-cell variability in overcoming a caspase activity threshold. Mol Syst Biol. 2015;11(5):803. https:\/\/doi.org\/10.15252\/msb.20145584.","journal-title":"Mol Syst Biol"},{"issue":"7","key":"8584_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17(7):395\u2013417. https:\/\/doi.org\/10.1038\/s41571-020-0341-y.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"8584_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/BF00214700","volume":"193","author":"PGH Clarke","year":"1996","unstructured":"Clarke PGH, Clarke S. Nineteenth century research on naturally occurring cell death and related phenomena. Anat Embryol (Berl). 1996;193(2):81\u201399. https:\/\/doi.org\/10.1007\/BF00214700.","journal-title":"Anat Embryol (Berl)"},{"issue":"1","key":"8584_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm3722","volume":"15","author":"PE Czabotar","year":"2014","unstructured":"Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49\u201363. https:\/\/doi.org\/10.1038\/nrm3722.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8584_CR14","doi-asserted-by":"publisher","unstructured":"Calzone L, Tournier L, Fourquet S, Thieffry D, Zhivotovsky B, Barillot E, et al. Mathematical modelling of cell-fate decision in response to death receptor engagement. PLoS Comput Biol. 2010;6(3):e1000702. https:\/\/doi.org\/10.1371\/journal.pcbi.1000702.","DOI":"10.1371\/journal.pcbi.1000702"},{"issue":"2","key":"8584_CR15","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1172\/JCI80420","volume":"125","author":"A Ashkenazi","year":"2015","unstructured":"Ashkenazi A. Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest. 2015;125(2):487\u201389. https:\/\/doi.org\/10.1172\/JCI80420.","journal-title":"J Clin Invest"},{"issue":"18","key":"8584_CR16","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1016\/j.cell.2022.07.025","volume":"185","author":"H Kalkavan","year":"2022","unstructured":"Kalkavan H, Chen MJ, Crawford JC, Quarato G, Fitzgerald P, Tait SWG, et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell. 2022;185(18):3356\u201374.e22. https:\/\/doi.org\/10.1016\/j.cell.2022.07.025.","journal-title":"Cell"},{"issue":"6","key":"8584_CR17","doi-asserted-by":"publisher","first-page":"189024","DOI":"10.1016\/j.bbcan.2023.189024","volume":"1878","author":"A Gielecinska","year":"2023","unstructured":"Gielecinska A, Kciuk M, Yahya EB, Ainane T, Mujwar S, Kontek R. Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents? Biochim et Biophys Acta (BBA) - Rev Cancer. 2023;1878(6):189024. https:\/\/doi.org\/10.1016\/j.bbcan.2023.189024.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"issue":"1","key":"8584_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1515\/jtim-2025-0004","volume":"13","author":"Z Guo","year":"2025","unstructured":"Guo Z, Liu Y, Chen D, Sun Y, Li D, Meng Y, et al. Targeting regulated cell death: apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity. J Transl Int Med. 2025;13(1):10\u201332. https:\/\/doi.org\/10.1515\/jtim-2025-0004.","journal-title":"J Transl Int Med"},{"issue":"1","key":"8584_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nchembio.1416","volume":"10","author":"SJ Dixon","year":"2014","unstructured":"Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10(1):9\u201317. https:\/\/doi.org\/10.1038\/nchembio.1416.","journal-title":"Nat Chem Biol"},{"issue":"7661","key":"8584_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y, Gao W, Shi X, Ding J, Liu W, He H, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature. 2017;547(7661):99\u2013103. https:\/\/doi.org\/10.1038\/nature22393.","journal-title":"Nature"},{"issue":"7545","key":"8584_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature14344","volume":"520","author":"L Jiang","year":"2015","unstructured":"Jiang L, Kon N, Li T, Wang SJ, Su T, Hibshoosh H, et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 2015;520(7545):57\u201362. https:\/\/doi.org\/10.1038\/nature14344.","journal-title":"Nature"},{"issue":"8","key":"8584_CR22","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1038\/s12276-023-01069-y","volume":"55","author":"E Lee","year":"2023","unstructured":"Lee E, Song CH, Bae SJ, Ha KT, Karki R. Regulated cell death pathways and their roles in homeostasis, infection, inflammation, and tumorigenesis. Exp Mol Med. 2023;55(8):1632\u201343. https:\/\/doi.org\/10.1038\/s12276-023-01069-y.","journal-title":"Exp Mol Med"},{"key":"8584_CR23","doi-asserted-by":"publisher","first-page":"1519119","DOI":"10.3389\/fonc.2025.1519119","volume":"15","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yi S, Luan M. Advances in non-apoptotic regulated cell death: implications for malignant tumor treatment. Front Oncol. 2025;15:1519119. https:\/\/doi.org\/10.3389\/fonc.2025.1519119.","journal-title":"Front Oncol"},{"issue":"1","key":"8584_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12943-024-02172-y","volume":"23","author":"R He","year":"2024","unstructured":"He R, Liu Y, Fu W, He X, Liu S, Xiao D, et al. Mechanisms and cross-talk of regulated cell death and their epigenetic modifications in tumor progression. Mol Cancer. 2024;23(1):267. https:\/\/doi.org\/10.1186\/s12943-024-02172-y.","journal-title":"Mol Cancer"},{"issue":"12","key":"8584_CR25","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1091\/mbc.e11-11-0926","volume":"23","author":"HL Tang","year":"2012","unstructured":"Tang HL, Tang HM, Mak KH, Hu S, Wang SS, Wong KM, et al. Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. MBoC. 2012;23(12):2240\u201352. https:\/\/doi.org\/10.1091\/mbc.e11-11-0926.","journal-title":"MBoC"},{"issue":"10","key":"8584_CR26","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax Monotherapy in patients with acute myelogenous leukemia. Cancer DiscovCancer Discov. 2016;6(10):1106\u201317. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0313.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"1","key":"8584_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/proteomes12010003","volume":"12","author":"D Fernandez-Lazaro","year":"2024","unstructured":"Fernandez-Lazaro D, Sanz B, Seco-Calvo J. The mechanisms of regulated cell death: structural and functional proteomic pathways induced or inhibited by a specific protein\u2014A narrative review. Proteomes. 2024;12(1):3. https:\/\/doi.org\/10.3390\/proteomes12010003.","journal-title":"Proteomes"},{"key":"8584_CR28","doi-asserted-by":"publisher","first-page":"1527286","DOI":"10.3389\/fphar.2024.1527286","volume":"15","author":"L Xiang","year":"2025","unstructured":"Xiang L, Li Q, Guan Z, Wang G, Yu X, Zhang X, et al. Oxyresveratrol as a novel ferroptosis inducer exhibits anticancer activity against breast cancer via the EGFR\/PI3K\/AKT\/GPX4 signalling axis. Front Pharmacol. 2025;15:1527286. https:\/\/doi.org\/10.3389\/fphar.2024.1527286.","journal-title":"Front Pharmacol"},{"issue":"2","key":"8584_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3390\/biology10020151","volume":"10","author":"H Li","year":"2021","unstructured":"Li H, Li L, Xue C, Huang R, Hu A, An X, et al. A novel ferroptosis-related gene signature predicts overall survival of breast cancer patients. Biol (Basel). 2021;10(2):151. https:\/\/doi.org\/10.3390\/biology10020151.","journal-title":"Biol (Basel)"},{"issue":"2","key":"8584_CR30","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","volume":"31","author":"D Tang","year":"2021","unstructured":"Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107\u201325. https:\/\/doi.org\/10.1038\/s41422-020-00441-1.","journal-title":"Cell Res"},{"issue":"1","key":"8584_CR31","doi-asserted-by":"publisher","first-page":"5364","DOI":"10.1038\/s41598-025-87982-w","volume":"15","author":"P Yu","year":"2025","unstructured":"Yu P, Xiao L, Hu K, Ling J, Chen Y, Liang R, et al. Comprehensive exploration of programmed cell death landscape in lung adenocarcinoma combining multi-omic analysis and experimental verification. Sci Rep. 2025;15(1):5364. https:\/\/doi.org\/10.1038\/s41598-025-87982-w.","journal-title":"Sci Rep"},{"issue":"1","key":"8584_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18(1):100. https:\/\/doi.org\/10.1186\/s12943-019-1029-8.","journal-title":"Mol Cancer"},{"key":"8584_CR33","doi-asserted-by":"publisher","unstructured":"Zheng Y, Feng N, Li C, Li Z. Natural products target programmed cell death signaling mechanisms to treat colorectal cancer. Front Pharmacol. 2025;16:- 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1565332.","DOI":"10.3389\/fphar.2025.1565332"},{"issue":"9","key":"8584_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4251\/wjgo.v10.i9.244","volume":"10","author":"P Ashokkumar","year":"2018","unstructured":"Ashokkumar P, Divya T, Kumar K, Dineshbabu V, Velavan B, Sudhandiran G. Colorectal carcinogenesis: insights into the cell death and signal transduction pathways: a review. WJGO. 2018;10(9):244\u201359. https:\/\/doi.org\/10.4251\/wjgo.v10.i9.244.","journal-title":"WJGO"},{"issue":"6","key":"8584_CR35","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ccell.2020.10.010","volume":"38","author":"S Bhatt","year":"2020","unstructured":"Bhatt S, Pioso MS, Olesinski EA, Yilma B, Ryan JA, Mashaka T, et al. Reduced mitochondrial apoptotic priming drives resistance to BH3 mimetics in acute myeloid leukemia. Cancer Cell. 2020;38(6):872\u201390.e6. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.010.","journal-title":"Cancer Cell"},{"issue":"25","key":"8584_CR36","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215\u201324. https:\/\/doi.org\/10.1182\/blood-2016-01-688796.","journal-title":"Blood"},{"issue":"7","key":"8584_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41419-022-05044-9","volume":"13","author":"de Souza I","year":"2022","unstructured":"de Souza I, Monteiro LKS, Guedes CB, Silva MM, Andrade-Tomaz M, Contieri B, et al. High levels of NRF2 sensitize temozolomide-resistant glioblastoma cells to ferroptosis via ABCC1\/MRP1 upregulation. Cell Death Dis. 2022;13(7):591. https:\/\/doi.org\/10.1038\/s41419-022-05044-9.","journal-title":"Cell Death Dis"},{"issue":"12","key":"8584_CR38","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1080\/09553002.2023.2235433","volume":"99","author":"W Huang","year":"2023","unstructured":"Huang W, He Y, Yang S, Xue X, Qin H, Sun T, et al. CA9 knockdown enhanced ionizing radiation-induced ferroptosis and radiosensitivity of hypoxic glioma cells. Int J Radiat Biol. 2023;99(12):1908\u201324. https:\/\/doi.org\/10.1080\/09553002.2023.2235433.","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"8584_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12964-023-01108-1","volume":"21","author":"S Wan","year":"2023","unstructured":"Wan S, Zhang G, Liu R, Abbas MN, Cui H. Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment. Cell Commun Signal. 2023;21(1):115. https:\/\/doi.org\/10.1186\/s12964-023-01108-1.","journal-title":"Cell Commun Signal"},{"issue":"6486","key":"8584_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aaw9872","volume":"368","author":"MA Badgley","year":"2020","unstructured":"Badgley MA, Kremer DM, Maurer HC, DelGiorno KE, Lee HJ, Purohit V, et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science. 2020;368(6486):85\u201389. https:\/\/doi.org\/10.1126\/science.aaw9872.","journal-title":"Science"},{"issue":"5","key":"8584_CR41","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","volume":"33","author":"J Tsoi","year":"2018","unstructured":"Tsoi J, Robert L, Paraiso K, Galvan C, Sheu KM, Lay J, et al. Multi-stage Differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell. 2018;33(5):890\u2013904.e5. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.017.","journal-title":"Cancer Cell"},{"issue":"7","key":"8584_CR42","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1158\/2159-8290.CD-13-0424","volume":"4","author":"DJ Konieczkowski","year":"2014","unstructured":"Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer DiscovCancer Discov. 2014;4(7):816\u201327. https:\/\/doi.org\/10.1158\/2159-8290.CD-13-0424.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"1","key":"8584_CR43","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s42003-022-03806-x","volume":"5","author":"X Lou","year":"2022","unstructured":"Lou X, Li K, Qian B, Li Y, Zhang D, Cui W. Pyroptosis correlates with tumor immunity and prognosis. Commun Biol. 2022;5(1):917. https:\/\/doi.org\/10.1038\/s42003-022-03806-x.","journal-title":"Commun Biol"},{"key":"8584_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2147\/IJN.S282489","volume":"16","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Xia M, Zhou Z, Hu X, Wang J, Zhang M, et al. p53 promoted ferroptosis in ovarian cancer cells treated with human serum incubated-Superparamagnetic iron oxides. IJN. 2021;16:283\u201396. https:\/\/doi.org\/10.2147\/IJN.S282489.","journal-title":"IJN"},{"key":"8584_CR45","doi-asserted-by":"publisher","first-page":"102458","DOI":"10.1016\/j.tice.2024.102458","volume":"89","author":"Y Wang","year":"2024","unstructured":"Wang Y, Yi Y. CISD2 downregulation participates in the ferroptosis process of human ovarian SKOV-3 cells through modulating the wild type p53-mediated GLS2\/SAT1\/SLC7A11 and Gpx4\/TRF signaling pathway. Tissue Cell. 2024;89:102458. https:\/\/doi.org\/10.1016\/j.tice.2024.102458.","journal-title":"Tissue Cell"},{"issue":"11","key":"8584_CR46","doi-asserted-by":"publisher","first-page":"8681","DOI":"10.1007\/s00432-023-04811-1","volume":"149","author":"W Yue","year":"2023","unstructured":"Yue W, Yupeng G, Jun C, Kui J. Apatinib combined with olaparib induces ferroptosis via a p53-dependent manner in ovarian cancer. J Cancer Res Clin Oncol. 2023;149(11):8681\u201389. https:\/\/doi.org\/10.1007\/s00432-023-04811-1.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"8584_CR47","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40170-020-00217-6","volume":"8","author":"KD Tousignant","year":"2020","unstructured":"Tousignant KD, Rockstroh A, Poad BLJ, Talebi A, Young RSE, Taherian Fard A, et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab. 2020;8(1):11. https:\/\/doi.org\/10.1186\/s40170-020-00217-6.","journal-title":"Cancer Metab"},{"key":"8584_CR48","doi-asserted-by":"publisher","unstructured":"Yang Y, Liu T, Hu C, Xia H, Liu W, Chen J, et al. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration\u2011resistant prostate cancer. Oncol Rep. 2021;45(4). https:\/\/doi.org\/10.3892\/or.2021.7976.","DOI":"10.3892\/or.2021.7976"},{"key":"8584_CR49","doi-asserted-by":"publisher","first-page":"100985","DOI":"10.1016\/j.drup.2023.100985","volume":"70","author":"J Wang","year":"2023","unstructured":"Wang J, Zeng L, Wu N, Liang Y, Jin J, Fan M, et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist Updates. 2023;70:100985. https:\/\/doi.org\/10.1016\/j.drup.2023.100985.","journal-title":"Drug Resist Updates"},{"key":"8584_CR50","doi-asserted-by":"publisher","unstructured":"Liu MR, Shi C, Song QY, Kang MJ, Jiang X, Liu H, et al. Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma. Hepatol Commun. 2023;7(10). https:\/\/doi.org\/10.1097\/HC9.0000000000000246.","DOI":"10.1097\/HC9.0000000000000246"},{"issue":"1","key":"8584_CR51","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jcmgh.2023.03.001","volume":"16","author":"JW-S Cheu","year":"2023","unstructured":"Cheu JW-S, Lee D, Li Q, Goh CC, Bao MH-R, Yuen VW-H, et al. Ferroptosis suppressor protein 1 inhibition promotes tumor ferroptosis and anti-tumor immune responses in Liver cancer. Cellular Mol Gastroenterol Hepatol. 2023;16(1):133\u201359. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.03.001.","journal-title":"Cellular Mol Gastroenterol Hepatol"},{"issue":"1","key":"8584_CR52","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41420-022-01161-8","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang H, Liu M, Zeng X, Zheng Y, Wang Y, Zhou Y. Cell death affecting the progression of gastric cancer. Cell Death Discov. 2022;8(1):377. https:\/\/doi.org\/10.1038\/s41420-022-01161-8.","journal-title":"Cell Death Discov"},{"issue":"2","key":"8584_CR53","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1039\/D4RA06377E","volume":"15","author":"SR Balusamy","year":"2025","unstructured":"Balusamy SR, Balamurugan M, Purushothaman S, Somasundaram S, Elsadek MF, Sohn D, et al. Apoptotic cell death of stomach cancer lines (AGS) induced by Co-NTB complex through cellular organelles and DNA damage. RSC Adv. 2025;15(2):739\u201347. https:\/\/doi.org\/10.1039\/D4RA06377E.","journal-title":"RSC Adv"},{"issue":"1","key":"8584_CR54","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41598-022-05426-1","volume":"12","author":"G Alzeeb","year":"2022","unstructured":"Alzeeb G, Arzur D, Trichet V, Talagas M, Corcos L, Le Jossic-Corcos C. Gastric cancer cell death analyzed by live cell imaging of spheroids. Sci Rep. 2022;12(1):1488. https:\/\/doi.org\/10.1038\/s41598-022-05426-1.","journal-title":"Sci Rep"},{"key":"8584_CR55","doi-asserted-by":"publisher","first-page":"149546","DOI":"10.1016\/j.gene.2025.149546","volume":"960","author":"M Yao","year":"2025","unstructured":"Yao M, Miao L, Wang X, Han Y. Targeting programmed cell death pathways in gastric cancer: a focus on pyroptosis, apoptosis, necroptosis and PANoptosis. Gene. 2025;960:149546. https:\/\/doi.org\/10.1016\/j.gene.2025.149546.","journal-title":"Gene"},{"key":"8584_CR56","doi-asserted-by":"publisher","unstructured":"Song Q, Liu S, Wu D, Cai A. Multiple programmed cell death patterns predict the prognosis and drug sensitivity in gastric cancer. Front. Immunol. 2025;16:- 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1511453.","DOI":"10.3389\/fimmu.2025.1511453"},{"key":"8584_CR57","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1017\/erm.2021.31","volume":"24","author":"MR Fabbrizi","year":"2022","unstructured":"Fabbrizi MR, Parsons JL. Cell death mechanisms in head and neck cancer cells in response to low and high-LET radiation. Expert Rev Mol Med. 2022;24:24. https:\/\/doi.org\/10.1017\/erm.2021.31.","journal-title":"Expert Rev Mol Med"},{"issue":"2","key":"8584_CR58","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41419-021-03474-5","volume":"12","author":"M Raudensk\u00e1","year":"2021","unstructured":"Raudensk\u00e1 M, Balvan J, Masa\u0159\u00edk M. Cell death in head and neck cancer pathogenesis and treatment. Cell Death Dis. 2021;12(2):192. https:\/\/doi.org\/10.1038\/s41419-021-03474-5.","journal-title":"Cell Death Dis"},{"key":"8584_CR59","doi-asserted-by":"publisher","first-page":"116132","DOI":"10.1016\/j.intimp.2025.116132","volume":"171","author":"S Chen","year":"2026","unstructured":"Chen S, Chen Y, Xu Y, Song B. Harnessing tumor cell death mechanisms to reshape the immune microenvironment: a novel approach for head and neck cancer therapy. Int Immunopharmacol. 2026;171:116132. https:\/\/doi.org\/10.1016\/j.intimp.2025.116132.","journal-title":"Int Immunopharmacol"},{"key":"8584_CR60","doi-asserted-by":"publisher","unstructured":"Xi Y, Gao L, Li S, Sun K, Chen P, Cai Z, et al. The role of novel programmed cell death in head and neck squamous cell carcinoma: from mechanisms to potential therapies. Front Pharmacol. 2023;14:- 2023. https:\/\/doi.org\/10.3389\/fphar.2023.1228985.","DOI":"10.3389\/fphar.2023.1228985"},{"issue":"4","key":"8584_CR61","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/jamaoto.2023.4694","volume":"150","author":"van den Besselaar Bn","year":"2024","unstructured":"van den Besselaar Bn, Sewnaik A, Hoesseini A, Dorr MC, Baatenburg de Jong RJ, Offerman MPJ, et al. Causes and ways of death in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2024;150(4):303\u201310. https:\/\/doi.org\/10.1001\/jamaoto.2023.4694.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"8","key":"8584_CR62","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","volume":"127","author":"C Touzeau","year":"2016","unstructured":"Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971\u201376. https:\/\/doi.org\/10.1182\/blood-2015-07-635383.","journal-title":"Blood"},{"key":"8584_CR63","doi-asserted-by":"publisher","first-page":"1127526","DOI":"10.3389\/fonc.2023.1127526","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu Y, Du Z, Huang J, Li T, Zhang J, Li Y, et al. Ferroptosis in hematological malignant tumors. Front Oncol. 2023;13:1127526. https:\/\/doi.org\/10.3389\/fonc.2023.1127526.","journal-title":"Front Oncol"},{"issue":"3","key":"8584_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1532\/IJH97.04107","volume":"80","author":"M Oancea","year":"2004","unstructured":"Oancea M, Mani A, Hussein MA, Almasan A. Apoptosis of multiple myeloma. Int J Hematol. 2004;80(3):224\u201331. https:\/\/doi.org\/10.1532\/IJH97.04107.","journal-title":"Int J Hematol"},{"issue":"1","key":"8584_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/aps.2011.143","volume":"33","author":"R Zeng","year":"2012","unstructured":"Zeng R, Chen Y, Zhao S, Cui G-H. Autophagy counteracts apoptosis in human multiple myeloma cells exposed to oridonin in vitro via regulating intracellular ROS and SIRT1. Acta Pharmacol Sin. 2012;33(1):91\u2013100. https:\/\/doi.org\/10.1038\/aps.2011.143.","journal-title":"Acta Pharmacol Sin"},{"issue":"1\u20132","key":"8584_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1023\/A:1009620027205","volume":"6","author":"D Chauhan","year":"2001","unstructured":"Chauhan D, Anderson KC. Apoptosis in multiple myeloma: therapeutic implications. Apoptosis. 2001;6(1\u20132):47\u201355. https:\/\/doi.org\/10.1023\/A:1009620027205.","journal-title":"Apoptosis"},{"issue":"6","key":"8584_CR67","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3324\/haematol.2021.279276","volume":"107","author":"D Soncini","year":"2021","unstructured":"Soncini D, Martinuzzi C, Becherini P, Gelli E, Ruberti S, Todoerti K, et al. Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to venetoclax treatment. Haematologica. 2021;107(6):1410\u201326. https:\/\/doi.org\/10.3324\/haematol.2021.279276.","journal-title":"Haematologica"},{"issue":"3","key":"8584_CR68","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 2018;25(3):486\u2013541. https:\/\/doi.org\/10.1038\/s41418-017-0012-4.","journal-title":"Cell Death Differ"},{"issue":"5","key":"8584_CR69","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41422-019-0164-5","volume":"29","author":"D Tang","year":"2019","unstructured":"Tang D, Kang R, Berghe TV, Vandenabeele P, Kroemer G. The molecular machinery of regulated cell death. Cell Res. 2019;29(5):347\u201364. https:\/\/doi.org\/10.1038\/s41422-019-0164-5.","journal-title":"Cell Res"},{"issue":"2","key":"8584_CR70","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","volume":"171","author":"BR Stockwell","year":"2017","unstructured":"Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox Biology, and disease. Cell. 2017;171(2):273\u201385. https:\/\/doi.org\/10.1016\/j.cell.2017.09.021.","journal-title":"Cell"},{"issue":"6","key":"8584_CR71","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.tcb.2020.02.009","volume":"30","author":"BR Stockwell","year":"2020","unstructured":"Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis. Trends Cell Biol. 2020;30(6):478\u201390. https:\/\/doi.org\/10.1016\/j.tcb.2020.02.009.","journal-title":"Trends Cell Biol"},{"issue":"7","key":"8584_CR72","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/s41418-021-00814-y","volume":"28","author":"D Moujalled","year":"2021","unstructured":"Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28(7):2029\u201344. https:\/\/doi.org\/10.1038\/s41418-021-00814-y.","journal-title":"Cell Death Differ"},{"issue":"6","key":"8584_CR73","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1007\/s12094-024-03769-x","volume":"27","author":"Y He","year":"2024","unstructured":"He Y, Wang X. A comprehensive investigation of associations between cell death pathways and molecular and clinical features in pan-cancer. Clin Transl Oncol. 2024;27(6):2731\u201349. https:\/\/doi.org\/10.1007\/s12094-024-03769-x.","journal-title":"Clin Transl Oncol"},{"key":"8584_CR74","doi-asserted-by":"publisher","unstructured":"Yan J, Wang J, Miao M, Shao Y. Comprehensive pan-cancer analysis indicates key gene of p53-independent apoptosis is a novel biomarker for clinical application and chemotherapy in colorectal cancer. Front. Immunol. 2025;16:- 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1571137.","DOI":"10.3389\/fimmu.2025.1571137"},{"issue":"5","key":"8584_CR75","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cell.2019.04.024","volume":"177","author":"DR Green","year":"2019","unstructured":"Green DR. The Coming Decade of cell death research: five riddles. Cell. 2019;177(5):1094\u2013107. https:\/\/doi.org\/10.1016\/j.cell.2019.04.024.","journal-title":"Cell"},{"issue":"7245","key":"8584_CR76","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature08012","volume":"459","author":"SL Spencer","year":"2009","unstructured":"Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature. 2009;459(7245):428\u201332. https:\/\/doi.org\/10.1038\/nature08012.","journal-title":"Nature"},{"issue":"1","key":"8584_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molcel.2008.02.012","volume":"30","author":"JG Albeck","year":"2008","unstructured":"Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell. 2008;30(1):11\u201325. https:\/\/doi.org\/10.1016\/j.molcel.2008.02.012.","journal-title":"Mol Cell"},{"issue":"1","key":"8584_CR78","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev-cancerbio-050216-121933","volume":"1","author":"A Letai","year":"2017","unstructured":"Letai A. Apoptosis and cancer. Annu Rev Cancer Biol. 2017;1(1):275\u201394. https:\/\/doi.org\/10.1146\/annurev-cancerbio-050216-121933.","journal-title":"Annu Rev Cancer Biol"},{"issue":"6","key":"8584_CR79","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.cell.2011.03.002","volume":"144","author":"SL Spencer","year":"2011","unstructured":"Spencer SL, Sorger PK. Measuring and modeling apoptosis in single cells. Cell. 2011;144(6):926\u201339. https:\/\/doi.org\/10.1016\/j.cell.2011.03.002.","journal-title":"Cell"},{"issue":"7","key":"8584_CR80","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.3390\/antiox11071324","volume":"11","author":"Y Tang","year":"2022","unstructured":"Tang Y, Zhang Z, Chen Y, Qin S, Zhou L, Gao W, et al. Metabolic adaptation-mediated cancer survival and progression in oxidative stress. Antioxid (Basel). 2022;11(7):1324. https:\/\/doi.org\/10.3390\/antiox11071324.","journal-title":"Antioxid (Basel)"},{"issue":"5","key":"8584_CR81","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.devcel.2010.03.014","volume":"18","author":"SWG Tait","year":"2010","unstructured":"Tait SWG, Parsons MJ, Llambi F, Bouchier-Hayes L, Connell S, Munoz-Pinedo C, et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell. 2010;18(5):802\u201313. https:\/\/doi.org\/10.1016\/j.devcel.2010.03.014.","journal-title":"Dev Cell"},{"issue":"1\u20132","key":"8584_CR82","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, SriRamaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1\u20132):317\u201331. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010.","journal-title":"Cell"},{"issue":"8","key":"8584_CR83","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1080\/15548627.2019.1582973","volume":"15","author":"M Chaurasia","year":"2019","unstructured":"Chaurasia M, Gupta S, Das A, Dwarakanath BS, Simonsen A, Sharma K. Radiation induces EIF2AK3\/PERK and ERN1\/IRE1 mediated pro-survival autophagy. Autophagy. 2019;15(8):1391\u2013406. https:\/\/doi.org\/10.1080\/15548627.2019.1582973.","journal-title":"Autophagy"},{"issue":"17","key":"8584_CR84","doi-asserted-by":"publisher","first-page":"8464","DOI":"10.7150\/thno.60028","volume":"11","author":"S Han","year":"2021","unstructured":"Han S, Zhu L, Zhu Y, Meng Y, Li J, Song P, et al. Targeting ATF4-dependent pro-survival autophagy to synergize glutaminolysis inhibition. Theranostics. 2021;11(17):8464\u201379. https:\/\/doi.org\/10.7150\/thno.60028.","journal-title":"Theranostics"},{"issue":"2","key":"8584_CR85","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molcel.2017.06.017","volume":"69","author":"C Hetz","year":"2018","unstructured":"Hetz C, Papa FR. The unfolded protein response and cell fate control. Mol Cell. 2018;69(2):169\u201381. https:\/\/doi.org\/10.1016\/j.molcel.2017.06.017.","journal-title":"Mol Cell"},{"issue":"1","key":"8584_CR86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027.","journal-title":"Cell"},{"key":"8584_CR87","doi-asserted-by":"publisher","unstructured":"Newton K, Wickliffe KE, Maltzman A, Dugger DL, Reja R, Zhang Y, et al. Author correction: activity of caspase-8 determines plasticity between cell death pathways. Nature. 2026;649(8095):E1. https:\/\/doi.org\/10.1038\/s41586-025-09980-2.","DOI":"10.1038\/s41586-025-09980-2"},{"issue":"7784","key":"8584_CR88","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41586-019-1770-6","volume":"575","author":"M Fritsch","year":"2019","unstructured":"Fritsch M, G\u00fcnther SD, Schwarzer R, Albert MC, Schorn F, Werthenbach JP, et al. Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis. Nature. 2019;575(7784):683\u201387. https:\/\/doi.org\/10.1038\/s41586-019-1770-6.","journal-title":"Nature"},{"issue":"1","key":"8584_CR89","doi-asserted-by":"publisher","first-page":"9015","DOI":"10.1038\/srep09015","volume":"5","author":"HL Tang","year":"2015","unstructured":"Tang HL, Tang HM, Fung MC, Hardwick JM. In vivo CaspaseTracker biosensor system for detecting anastasis and non-apoptotic caspase activity. Sci Rep. 2015;5(1):9015. https:\/\/doi.org\/10.1038\/srep09015.","journal-title":"Sci Rep"},{"key":"8584_CR90","doi-asserted-by":"publisher","first-page":"5","DOI":"10.7554\/eLife.10936","volume":"5","author":"X Ding","year":"2016","unstructured":"Ding X, Sun G, Argaw YG, Wong JO, Easwaran S, Montell DJ. CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. Elife. 2016;5:5. https:\/\/doi.org\/10.7554\/eLife.10936.","journal-title":"Elife"},{"key":"8584_CR91","doi-asserted-by":"publisher","unstructured":"Zhang W, Chattrakarn S, Chen F, Chai H, Maranga M, Zhang J. Targeting cancer drug-tolerant persister cells in minimal residual disease. Int J Drug Discov Pharmacol. 2025;100011. https:\/\/doi.org\/10.53941\/ijddp.2025.100011.","DOI":"10.53941\/ijddp.2025.100011"},{"issue":"7658","key":"8584_CR92","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431\u201335. https:\/\/doi.org\/10.1038\/nature22794.","journal-title":"Nature"},{"key":"8584_CR93","doi-asserted-by":"publisher","unstructured":"Legewie S, Bluthgen N, Herzel H. Mathematical modeling identifies inhibitors of apoptosis as mediators of positive feedback and bistability. PLoS Comput Biol. 2006;2(9):e120. https:\/\/doi.org\/10.1371\/journal.pcbi.0020120.","DOI":"10.1371\/journal.pcbi.0020120"},{"key":"8584_CR94","doi-asserted-by":"publisher","unstructured":"Nano M, Mondo JA, Harwood J, Balasanyan V, Montell DJ. Cell survival following direct executioner-caspase activation. Proc Natl Acad Sci USA. 2023;120(4):e2216531120. https:\/\/doi.org\/10.1073\/pnas.2216531120.","DOI":"10.1073\/pnas.2216531120"},{"issue":"3","key":"8584_CR95","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/febs.14714","volume":"286","author":"YN Gong","year":"2019","unstructured":"Gong YN, Crawford JC, Heckmann BL, Green DR. To the edge of cell death and back. The FEBS J. 2019;286(3):430\u201340. https:\/\/doi.org\/10.1111\/febs.14714.","journal-title":"The FEBS J"},{"issue":"23","key":"8584_CR96","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1091\/mbc.e09-07-0649","volume":"20","author":"L Lartigue","year":"2009","unstructured":"Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B, Newmeyer DD. Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Mol Biol Cell. 2009;20(23):4871\u201384. https:\/\/doi.org\/10.1091\/mbc.e09-07-0649.","journal-title":"MBoC"},{"issue":"5","key":"8584_CR97","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.cell.2007.03.045","volume":"129","author":"A Colell","year":"2007","unstructured":"Colell A, Ricci JE, Tait S, Milasta S, Maurer U, Bouchier-Hayes L, et al. GAPDH and autophagy preserve survival after apoptotic cytochrome c release in the absence of caspase activation. Cell. 2007;129(5):983\u201397. https:\/\/doi.org\/10.1016\/j.cell.2007.03.045.","journal-title":"Cell"},{"issue":"36","key":"8584_CR98","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1038\/onc.2010.242","volume":"29","author":"MM Lovric","year":"2010","unstructured":"Lovric MM, Hawkins CJ. TRAIL treatment provokes mutations in surviving cells. Oncogene. 2010;29(36):5048\u201360. https:\/\/doi.org\/10.1038\/onc.2010.242.","journal-title":"Oncogene"},{"issue":"1","key":"8584_CR99","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25(1):65\u201380. https:\/\/doi.org\/10.1038\/cdd.2017.186.","journal-title":"Cell Death Differ"},{"issue":"1","key":"8584_CR100","doi-asserted-by":"publisher","first-page":"107845","DOI":"10.1016\/j.celrep.2020.107845","volume":"32","author":"Z Inde","year":"2020","unstructured":"Inde Z, Forcina GC, Denton K, Dixon SJ. Kinetic heterogeneity of cancer cell fractional killing. Cell Rep. 2020;32(1):107845. https:\/\/doi.org\/10.1016\/j.celrep.2020.107845.","journal-title":"Cell Rep"},{"issue":"3","key":"8584_CR101","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cell.2016.03.025","volume":"165","author":"AL Paek","year":"2016","unstructured":"Paek AL, Liu JC, Loewer A, Forrester WC, Lahav G. Cell-to-cell variation in p53 dynamics leads to fractional killing. Cell. 2016;165(3):631\u201342. https:\/\/doi.org\/10.1016\/j.cell.2016.03.025.","journal-title":"Cell"},{"issue":"14","key":"8584_CR102","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1091\/mbc.e12-10-0737","volume":"24","author":"DA Flusberg","year":"2013","unstructured":"Flusberg DA, Roux J, Spencer SL, Sorger PK. Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol Biol Cell. 2013;24(14):2186\u2013200. https:\/\/doi.org\/10.1091\/mbc.e12-10-0737.","journal-title":"MBoC"},{"issue":"7679","key":"8584_CR103","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature24297","volume":"551","author":"MJ Hangauer","year":"2017","unstructured":"Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature. 2017;551(7679):247\u201350. https:\/\/doi.org\/10.1038\/nature24297.","journal-title":"Nature"},{"issue":"1","key":"8584_CR104","doi-asserted-by":"publisher","first-page":"905","DOI":"10.15252\/msb.20166796","volume":"13","author":"M Fallahi-Sichani","year":"2017","unstructured":"Fallahi-Sichani M, Becker V, Izar B, Baker GJ, Lin JR, Boswell SA, et al. Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state. Mol Syst Biol. 2017;13(1):905. https:\/\/doi.org\/10.15252\/msb.20166796.","journal-title":"Mol Syst Biol"},{"issue":"6059","key":"8584_CR105","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1126\/science.1206727","volume":"334","author":"T Ni Chonghaile","year":"2011","unstructured":"Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334(6059):1129\u201333. https:\/\/doi.org\/10.1126\/science.1206727.","journal-title":"Science"},{"issue":"5","key":"8584_CR106","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","volume":"9","author":"M Certo","year":"2006","unstructured":"Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351\u201365. https:\/\/doi.org\/10.1016\/j.ccr.2006.03.027.","journal-title":"Cancer Cell"},{"issue":"7664","key":"8584_CR107","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature23007","volume":"547","author":"VS Viswanathan","year":"2017","unstructured":"Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. 2017;547(7664):453\u201357. https:\/\/doi.org\/10.1038\/nature23007.","journal-title":"Nature"},{"issue":"10","key":"8584_CR108","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1083\/jcb.201706134","volume":"216","author":"G Sun","year":"2017","unstructured":"Sun G, Guzman E, Balasanyan V, Conner CM, Wong K, Zhou HR, et al. A molecular signature for anastasis, recovery from the brink of apoptotic cell death. J Cell Biol. 2017;216(10):3355\u201368. https:\/\/doi.org\/10.1083\/jcb.201706134.","journal-title":"J Cell Biol"},{"issue":"11","key":"8584_CR109","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/bjc.2015.146","volume":"112","author":"AO Pisco","year":"2015","unstructured":"Pisco AO, Huang S. Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: \u2018what does not kill me strengthens me\u2019. Br J Cancer. 2015;112(11):1725\u201332. https:\/\/doi.org\/10.1038\/bjc.2015.146.","journal-title":"Br J Cancer"},{"issue":"5","key":"8584_CR110","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nrg2556","volume":"10","author":"A Brock","year":"2009","unstructured":"Brock A, Chang H, Huang S. Non-genetic heterogeneity \u2014 a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet. 2009;10(5):336\u201342. https:\/\/doi.org\/10.1038\/nrg2556.","journal-title":"Nat Rev Genet"},{"issue":"2","key":"8584_CR111","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s44321-023-00011-z","volume":"16","author":"X Wu","year":"2024","unstructured":"Wu X, Nagy LE, Gautheron J. Mediators of necroptosis: from cell death to metabolic regulation. EMBO Mol Med. 2024;16(2):219\u201337. https:\/\/doi.org\/10.1038\/s44321-023-00011-z.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"8584_CR112","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41420-025-02743-y","volume":"11","author":"Y Wen","year":"2025","unstructured":"Wen Y, Lin Z, Jiang Z, Li Y, Wu T. Targeting the redox-programmed cell death axis in breast cancer: from molecular mechanisms to therapeutic resistance. Cell Death Discov. 2025;11(1):441. https:\/\/doi.org\/10.1038\/s41420-025-02743-y.","journal-title":"Cell Death Discov"},{"issue":"3","key":"8584_CR113","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell MetabCell Metab. 2022;34(3):355\u201377. https:\/\/doi.org\/10.1016\/j.cmet.2022.01.007.","journal-title":"Cell MetabCell Metab"},{"issue":"1","key":"8584_CR114","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","volume":"23","author":"NN Pavlova","year":"2016","unstructured":"Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell MetabCell Metab. 2016;23(1):27\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2015.12.006.","journal-title":"Cell MetabCell Metab"},{"issue":"6487","key":"8584_CR115","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):6487. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"issue":"2","key":"8584_CR116","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","volume":"24","author":"KC Patra","year":"2013","unstructured":"Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213\u201328. https:\/\/doi.org\/10.1016\/j.ccr.2013.06.014.","journal-title":"Cancer Cell"},{"issue":"7598","key":"8584_CR117","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature17393","volume":"532","author":"L Jiang","year":"2016","unstructured":"Jiang L, Shestov AA, Swain P, Yang C, Parker SJ, Wang QA, et al. Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 2016;532(7598):255\u201358. https:\/\/doi.org\/10.1038\/nature17393.","journal-title":"Nature"},{"issue":"2","key":"8584_CR118","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell. 2015;27(2):211\u201322. https:\/\/doi.org\/10.1016\/j.ccell.2014.11.019.","journal-title":"Cancer Cell"},{"issue":"12","key":"8584_CR119","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1016\/j.bbamcr.2016.09.012","volume":"1863","author":"M Redza-Dutordoir","year":"2016","unstructured":"Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim et Biophys Acta (BBA) - Mol Cell Res. 2016;1863(12):2977\u201392. https:\/\/doi.org\/10.1016\/j.bbamcr.2016.09.012.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Res"},{"key":"8584_CR120","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cophys.2018.03.005","volume":"3","author":"PS Jeng","year":"2018","unstructured":"Jeng PS, Inoue-Yamauchi A, Hsieh JJ, Cheng EH. BH3-dependent and independent activation of BAX and BAK in mitochondrial apoptosis. Curr Opin Physiol. 2018;3:71\u201381. https:\/\/doi.org\/10.1016\/j.cophys.2018.03.005.","journal-title":"Curr Opin Physiol"},{"issue":"1","key":"8584_CR121","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev-cancerbio-041916-065808","volume":"1","author":"CR Reczek","year":"2017","unstructured":"Reczek CR, Chandel NS. The two faces of reactive oxygen species in cancer. Annu Rev Cancer Biol. 2017;1(1):79\u201398. https:\/\/doi.org\/10.1146\/annurev-cancerbio-041916-065808.","journal-title":"Annu Rev Cancer Biol"},{"issue":"1","key":"8584_CR122","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27(1):441\u201364. https:\/\/doi.org\/10.1146\/annurev-cellbio-092910-154237.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"8584_CR123","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","volume":"162","author":"LB Sullivan","year":"2015","unstructured":"Sullivan LB, Gui DY, Hosios AM, Bush LN, Freinkman E, Vander Heiden MG. Supporting Aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015;162(3):552\u201363. https:\/\/doi.org\/10.1016\/j.cell.2015.07.017.","journal-title":"Cell"},{"issue":"2","key":"8584_CR124","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.molcel.2012.09.025","volume":"48","author":"LA Sena","year":"2012","unstructured":"Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48(2):158\u201367. https:\/\/doi.org\/10.1016\/j.molcel.2012.09.025.","journal-title":"Mol Cell"},{"issue":"8","key":"8584_CR125","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/ars.2007.1957","volume":"10","author":"D Trachootham","year":"2008","unstructured":"Trachootham D, Lu W, Ogasawara MA, Valle NR-D, Huang P. Redox regulation of cell survival. Antioxid Redox Signal. 2008;10(8):1343\u201374. https:\/\/doi.org\/10.1089\/ars.2007.1957.","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"8584_CR126","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.tibs.2014.06.005","volume":"39","author":"KC Patra","year":"2014","unstructured":"Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochemical Sci. 2014;39(8):347\u201354. https:\/\/doi.org\/10.1016\/j.tibs.2014.06.005.","journal-title":"Trends Biochemical Sci"},{"issue":"7504","key":"8584_CR127","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature13236","volume":"510","author":"J Fan","year":"2014","unstructured":"Fan J, Ye J, Kamphorst JJ, Shlomi T, Thompson CB, Rabinowitz JD. Quantitative flux analysis reveals folate-dependent NADPH production. Nature. 2014;510(7504):298\u2013302. https:\/\/doi.org\/10.1038\/nature13236.","journal-title":"Nature"},{"issue":"7354","key":"8584_CR128","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nature10189","volume":"475","author":"GM DeNicola","year":"2011","unstructured":"DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011;475(7354):106\u201309. https:\/\/doi.org\/10.1038\/nature10189.","journal-title":"Nature"},{"issue":"1","key":"8584_CR129","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nchembio.2238","volume":"13","author":"VE Kagan","year":"2017","unstructured":"Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, Croix CS, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13(1):81\u201390. https:\/\/doi.org\/10.1038\/nchembio.2238.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"8584_CR130","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","volume":"162","author":"K Birsoy","year":"2015","unstructured":"Birsoy K, Wang T, Chen WW, Freinkman E, Abu-Remaileh M, Sabatini DM. An essential role of the mitochondrial electron transport chain in cell proliferation is to enable Aspartate synthesis. Cell. 2015;162(3):540\u201351. https:\/\/doi.org\/10.1016\/j.cell.2015.07.016.","journal-title":"Cell"},{"issue":"1","key":"8584_CR131","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nchembio.2239","volume":"13","author":"S Doll","year":"2017","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13(1):91\u201398. https:\/\/doi.org\/10.1038\/nchembio.2239.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"8584_CR132","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41589-022-01249-3","volume":"19","author":"von Krusenstiern An","year":"2023","unstructured":"von Krusenstiern An, Robson RN, Qian N, Qiu B, Hu F, Reznik E, et al. Identification of essential sites of lipid peroxidation in ferroptosis. Nat Chem Biol. 2023;19(6):719\u201330. https:\/\/doi.org\/10.1038\/s41589-022-01249-3.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"8584_CR133","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/CM9.0000000000002239","volume":"136","author":"L Gong","year":"2023","unstructured":"Gong L, Huang D, Shi Y, Liang Z, Bu H. Regulated cell death in cancer: from pathogenesis to treatment. Chin Med J. 2023;136(6):653\u201365. https:\/\/doi.org\/10.1097\/CM9.0000000000002239.","journal-title":"Chin Med J"},{"issue":"1","key":"8584_CR134","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Martinez-Reyes","year":"2020","unstructured":"Martinez-Reyes I, Chandel NS. Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun. 2020;11(1):102. https:\/\/doi.org\/10.1038\/s41467-019-13668-3.","journal-title":"Nat Commun"},{"issue":"1","key":"8584_CR135","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.cmet.2015.05.023","volume":"22","author":"C Canto","year":"2015","unstructured":"Canto C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell MetabCell Metab. 2015;22(1):31\u201353. https:\/\/doi.org\/10.1016\/j.cmet.2015.05.023.","journal-title":"Cell MetabCell Metab"},{"issue":"2","key":"8584_CR136","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm.2016.140","volume":"18","author":"BR Sabari","year":"2017","unstructured":"Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 2017;18(2):90\u2013101. https:\/\/doi.org\/10.1038\/nrm.2016.140.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"8584_CR137","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","volume":"169","author":"MD Buck","year":"2017","unstructured":"Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic instruction of immunity. Cell. 2017;169(4):570\u201386. https:\/\/doi.org\/10.1016\/j.cell.2017.04.004.","journal-title":"Cell"},{"key":"8584_CR138","doi-asserted-by":"publisher","unstructured":"Vanden Berghe T, Kaiser WJ, Bertrand MJ, Vandenabeele P. Molecular crosstalk between apoptosis, necroptosis, and survival signaling. Mol Cellular Oncol. 2015;2(4):e975093. https:\/\/doi.org\/10.4161\/23723556.2014.975093.","DOI":"10.4161\/23723556.2014.975093"},{"issue":"1","key":"8584_CR139","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-015-0321-5","volume":"14","author":"Z Su","year":"2015","unstructured":"Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer. 2015;14(1):48. https:\/\/doi.org\/10.1186\/s12943-015-0321-5.","journal-title":"Mol Cancer"},{"key":"8584_CR140","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semcancer.2014.05.002","volume":"31","author":"S Fulda","year":"2015","unstructured":"Fulda S. Targeting apoptosis for anticancer therapy. Semin Cancer Biol. 2015;31:84\u201388. https:\/\/doi.org\/10.1016\/j.semcancer.2014.05.002.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"8584_CR141","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s41065-025-00564-8","volume":"162","author":"S Ghorbian","year":"2025","unstructured":"Ghorbian S. Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives. Hereditas. 2025;162(1):188. https:\/\/doi.org\/10.1186\/s41065-025-00564-8.","journal-title":"Hereditas"},{"issue":"2","key":"8584_CR142","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trecan.2018.01.001","volume":"4","author":"R Salgia","year":"2018","unstructured":"Salgia R, Kulkarni P. The Genetic\/Non-genetic duality of drug \u2018resistance\u2019 in cancer. Trends Cancer. 2018;4(2):110\u201318. https:\/\/doi.org\/10.1016\/j.trecan.2018.01.001.","journal-title":"Trends Cancer"},{"issue":"1","key":"8584_CR143","doi-asserted-by":"publisher","first-page":"193","DOI":"10.18632\/oncotarget.28382","volume":"14","author":"MV Blagosklonny","year":"2023","unstructured":"Blagosklonny MV. Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells. Oncotarget. 2023;14(1):193\u2013206. https:\/\/doi.org\/10.18632\/oncotarget.28382.","journal-title":"Oncotarget"},{"issue":"6","key":"8584_CR144","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.tcb.2023.10.002","volume":"34","author":"FJH Whiting","year":"2024","unstructured":"Whiting FJH, Househam J, Baker AM, Sottoriva A, Graham TA. Phenotypic noise and plasticity in cancer evolution. Trends Cell Biol. 2024;34(6):451\u201364. https:\/\/doi.org\/10.1016\/j.tcb.2023.10.002.","journal-title":"Trends Cell Biol"},{"issue":"5\u20136","key":"8584_CR145","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.semcancer.2012.04.001","volume":"22","author":"C Scheel","year":"2012","unstructured":"Scheel C, Weinberg RA. Cancer stem cells and epithelial\u2013mesenchymal transition: concepts and molecular links. Semin Cancer Biol. 2012;22(5\u20136):396\u2013403. https:\/\/doi.org\/10.1016\/j.semcancer.2012.04.001.","journal-title":"Semin Cancer Biol"},{"issue":"28","key":"8584_CR146","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1038\/onc.2014.314","volume":"34","author":"P Ramos","year":"2015","unstructured":"Ramos P, Bentires-Alj M. Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene. 2015;34(28):3617\u201326. https:\/\/doi.org\/10.1038\/onc.2014.314.","journal-title":"Oncogene"},{"key":"8584_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/4516454","volume":"2018","author":"P Gener","year":"2018","unstructured":"Gener P, Seras-Franzoso J, Callejo PG, Andrade F, Rafael D, Mart\u00ednez F, et al. Dynamism, sensitivity, and consequences of mesenchymal and stem-like phenotype of cancer cells. Stem Cells Int. 2018;2018:1\u201312. https:\/\/doi.org\/10.1155\/2018\/4516454.","journal-title":"STEM Cells Int"},{"issue":"11","key":"8584_CR148","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/pin.12447","volume":"66","author":"T Ishiwata","year":"2016","unstructured":"Ishiwata T. Cancer stem cells and epithelial-mesenchymal transition: novel therapeutic targets for cancer. Pathol Int. 2016;66(11):601\u201308. https:\/\/doi.org\/10.1111\/pin.12447.","journal-title":"Pathol Int"},{"issue":"4","key":"8584_CR149","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/med.21948","volume":"43","author":"HL Ang","year":"2023","unstructured":"Ang HL, Mohan CD, Shanmugam MK, Leong HC, Makvandi P, Rangappa KS, et al. Mechanism of epithelial-mesenchymal transition in cancer and its regulation by natural compounds. Med Res Rev. 2023;43(4):1141\u2013200. https:\/\/doi.org\/10.1002\/med.21948.","journal-title":"Med Res Rev"},{"key":"8584_CR150","doi-asserted-by":"publisher","unstructured":"Tolue Ghasaban F, Ghanei M, Mahmoudian RA, Taghehchian N, Abbaszadegan MR, Moghbeli M. MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells. Heliyon. 2024;10(9):e30599. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e30599.","DOI":"10.1016\/j.heliyon.2024.e30599"},{"issue":"1","key":"8584_CR151","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu Y, Chan YT, Tan HY, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer. 2020;19(1):79. https:\/\/doi.org\/10.1186\/s12943-020-01197-3.","journal-title":"Mol Cancer"},{"issue":"7547","key":"8584_CR152","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature14336","volume":"520","author":"AC Obenauf","year":"2015","unstructured":"Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520(7547):368\u201372. https:\/\/doi.org\/10.1038\/nature14336.","journal-title":"Nature"},{"issue":"2","key":"8584_CR153","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrm3737","volume":"15","author":"T Vanden Berghe","year":"2014","unstructured":"Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15(2):135\u201347. https:\/\/doi.org\/10.1038\/nrm3737.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8584_CR154","doi-asserted-by":"publisher","unstructured":"Jawwad T, Kamkaew M, Phongkitkarun K, Chusorn P, Jamnongsong S, Lam EW-F, et al. Exploring the single-cell dynamics of FOXM1 under cell cycle perturbations. Cell Proliferation. 2025;58(8):e70019. https:\/\/doi.org\/10.1111\/cpr.70019.","DOI":"10.1111\/cpr.70019"},{"issue":"12","key":"8584_CR155","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine JC, Dawson SJ, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20(12):743\u201356. https:\/\/doi.org\/10.1038\/s41568-020-00302-4.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8584_CR156","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-023-01383-x","volume":"8","author":"ZD Shi","year":"2023","unstructured":"Shi ZD, Pang K, Wu ZX, Dong Y, Hao L, Qin JX, et al. Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. Sig Transduct Target Ther. 2023;8(1):113. https:\/\/doi.org\/10.1038\/s41392-023-01383-x.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"8584_CR157","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41392-020-00313-5","volume":"5","author":"S Qin","year":"2020","unstructured":"Qin S, Jiang J, Lu Y, Nice EC, Huang C, Zhang J, et al. Emerging role of tumor cell plasticity in modifying therapeutic response. Sig Transduct Target Ther. 2020;5(1):228. https:\/\/doi.org\/10.1038\/s41392-020-00313-5.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"8584_CR158","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-pathmechdis-051222-115023","volume":"20","author":"A Moyer","year":"2025","unstructured":"Moyer A, Tanaka K, Cheng EH. Apoptosis in cancer Biology and therapy. Annu Rev Pathol: Mechanisms Disease. 2025;20(1):303\u201328. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-051222-115023.","journal-title":"Annu Rev Pathol: Mechanisms Disease"},{"issue":"5","key":"8584_CR159","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"issue":"2","key":"8584_CR160","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nrc2297","volume":"8","author":"AG Letai","year":"2008","unstructured":"Letai AG. Diagnosing and exploiting cancer\u2019s addiction to blocks in apoptosis. Nat Rev Cancer. 2008;8(2):121\u201332. https:\/\/doi.org\/10.1038\/nrc2297.","journal-title":"Nat Rev Cancer"},{"key":"8584_CR161","doi-asserted-by":"publisher","first-page":"1177466","DOI":"10.3389\/fonc.2023.1177466","volume":"13","author":"XW Liang","year":"2023","unstructured":"Liang XW, Liu B, Chen JC, Cao Z, Chu FR, Lin X, et al. Characteristics and molecular mechanism of drug-tolerant cells in cancer: a review. Front Oncol. 2023;13:1177466. https:\/\/doi.org\/10.3389\/fonc.2023.1177466.","journal-title":"Front Oncol"},{"issue":"9","key":"8584_CR162","doi-asserted-by":"publisher","first-page":"14535","DOI":"10.1002\/jcp.28160","volume":"234","author":"V Das","year":"2019","unstructured":"Das V, Bhattacharya S, Chikkaputtaiah C, Hazra S, Pal M. The basics of epithelial\u2013mesenchymal transition (EMT): a study from a structure, dynamics, and functional perspective. J Cellular Physiol. 2019;234(9):14535\u201355. https:\/\/doi.org\/10.1002\/jcp.28160.","journal-title":"J Cellular Physiol"},{"issue":"6","key":"8584_CR163","doi-asserted-by":"publisher","first-page":"100773","DOI":"10.1016\/j.tranon.2020.100773","volume":"13","author":"D Ribatti","year":"2020","unstructured":"Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: a historical overview. Transl Oncol. 2020;13(6):100773. https:\/\/doi.org\/10.1016\/j.tranon.2020.100773.","journal-title":"Transl Oncol"},{"issue":"4","key":"8584_CR164","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.gendis.2022.02.007","volume":"10","author":"U Anand","year":"2023","unstructured":"Anand U, Dey A, Chandel AKS, Sanyal R, Mishra A, Pandey DK, et al. Cancer chemotherapy and beyond: current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Dis. 2023;10(4):1367\u2013401. https:\/\/doi.org\/10.1016\/j.gendis.2022.02.007.","journal-title":"Genes & Dis"},{"issue":"4","key":"8584_CR165","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237\u201351. https:\/\/doi.org\/10.1038\/nrc3237.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8584_CR166","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12964-016-0142-1","volume":"14","author":"SG Kimani","year":"2016","unstructured":"Kimani SG, Kumar S, Davra V, Chang YJ, Kasikara C, Geng K, et al. Normalization of TAM post-receptor signaling reveals a cell invasive signature for axl tyrosine kinase. Cell Commun Signal. 2016;14(1):19. https:\/\/doi.org\/10.1186\/s12964-016-0142-1.","journal-title":"Cell Commun Signal"},{"key":"8584_CR167","doi-asserted-by":"publisher","unstructured":"Ramazi S, Dadzadi M, Sahafnejad Z, Allahverdi A. Epigenetic regulation in lung cancer. MedComm. 2023;4, 4(6):e401. https:\/\/doi.org\/10.1002\/mco2.401.","DOI":"10.1002\/mco2.401"},{"key":"8584_CR168","doi-asserted-by":"publisher","unstructured":"Luo K. Signaling cross talk between TGF-\u03b2\/Smad and other signaling pathways. Cold Spring Harb Perspect Biol. 2017;9(1):a022137. https:\/\/doi.org\/10.1101\/cshperspect.a022137.","DOI":"10.1101\/cshperspect.a022137"},{"issue":"11","key":"8584_CR169","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1089\/ars.2011.4280","volume":"16","author":"E Giannoni","year":"2012","unstructured":"Giannoni E, Parri M, Chiarugi P. EMT and oxidative stress: a bidirectional interplay affecting tumor malignancy. Antioxid Redox Signal. 2012;16(11):1248\u201363. https:\/\/doi.org\/10.1089\/ars.2011.4280.","journal-title":"Antioxid Redox Signal"},{"key":"8584_CR170","doi-asserted-by":"publisher","first-page":"115425","DOI":"10.1016\/j.biopha.2023.115425","volume":"166","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Li T, Sun L, Yuan Y, Zhu Y. Potential mechanisms of cancer-associated fibroblasts in therapeutic resistance. Biomed Pharmacother. 2023;166:115425. https:\/\/doi.org\/10.1016\/j.biopha.2023.115425.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"8584_CR171","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tips.2019.04.005","volume":"40","author":"X Zhuang","year":"2019","unstructured":"Zhuang X, Zhang H, Hu G. Cancer and microenvironment plasticity: Double-edged Swords in metastasis. Trends Pharmacological Sci. 2019;40(6):419\u201329. https:\/\/doi.org\/10.1016\/j.tips.2019.04.005.","journal-title":"Trends Pharmacological Sci"},{"issue":"4","key":"8584_CR172","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","volume":"8","author":"KH Vousden","year":"2007","unstructured":"Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275\u201383. https:\/\/doi.org\/10.1038\/nrm2147.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"8584_CR173","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3390\/cancers3010994","volume":"3","author":"T Ozaki","year":"2011","unstructured":"Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers (Basel). 2011;3(1):994\u20131013. https:\/\/doi.org\/10.3390\/cancers3010994.","journal-title":"Cancers (Basel)"},{"issue":"5660","key":"8584_CR174","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1092734","volume":"303","author":"JE Chipuk","year":"2004","unstructured":"Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 2004;303(5660):1010\u201314. https:\/\/doi.org\/10.1126\/science.1092734.","journal-title":"Science"},{"issue":"9","key":"8584_CR175","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/nrc883","volume":"2","author":"S Cory","year":"2002","unstructured":"Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2(9):647\u201356. https:\/\/doi.org\/10.1038\/nrc883.","journal-title":"Nat Rev Cancer"},{"issue":"40","key":"8584_CR176","doi-asserted-by":"publisher","first-page":"31546","DOI":"10.1074\/jbc.M001363200","volume":"275","author":"BW Johnson","year":"2000","unstructured":"Johnson BW, Cepero E, Boise LH. Bcl-xL inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-\u03b1. J Biol Chem. 2000;275(40):31546\u201353. https:\/\/doi.org\/10.1074\/jbc.M001363200.","journal-title":"J Biol Chem"},{"issue":"11","key":"8584_CR177","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19(11):1294\u2013305. https:\/\/doi.org\/10.1101\/gad.1304105.","journal-title":"Genes Dev"},{"issue":"2","key":"8584_CR178","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ccr.2007.07.001","volume":"12","author":"J Deng","year":"2007","unstructured":"Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007;12(2):171\u201385. https:\/\/doi.org\/10.1016\/j.ccr.2007.07.001.","journal-title":"Cancer Cell"},{"issue":"5","key":"8584_CR179","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","volume":"10","author":"van Delft Mf","year":"2006","unstructured":"van Delft Mf, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389\u201399. https:\/\/doi.org\/10.1016\/j.ccr.2006.08.027.","journal-title":"Cancer Cell"},{"issue":"5","key":"8584_CR180","doi-asserted-by":"publisher","first-page":"118987","DOI":"10.1016\/j.bbamcr.2021.118987","volume":"1868","author":"S Kehr","year":"2021","unstructured":"Kehr S, Vogler M. It\u2019s time to die: BH3 mimetics in solid tumors. Biochim et Biophys Acta (BBA) - Mol Cell Res. 2021;1868(5):118987. https:\/\/doi.org\/10.1016\/j.bbamcr.2021.118987.","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Res"},{"issue":"7","key":"8584_CR181","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381\u201396. https:\/\/doi.org\/10.1038\/s41568-022-00459-0.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8584_CR182","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R. Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer. 2022;21(1):47. https:\/\/doi.org\/10.1186\/s12943-022-01530-y.","journal-title":"Mol Cancer"},{"key":"8584_CR183","doi-asserted-by":"publisher","first-page":"891652","DOI":"10.3389\/fonc.2022.891652","volume":"12","author":"TB Emran","year":"2022","unstructured":"Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MFR, et al. Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12:891652. https:\/\/doi.org\/10.3389\/fonc.2022.891652.","journal-title":"Front Oncol"},{"issue":"2","key":"8584_CR184","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","volume":"30","author":"G Lei","year":"2020","unstructured":"Lei G, Zhang Y, Koppula P, Liu X, Zhang J, Lin SH, et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 2020;30(2):146\u201362. https:\/\/doi.org\/10.1038\/s41422-019-0263-3.","journal-title":"Cell Res"},{"issue":"7755","key":"8584_CR185","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-019-1170-y","volume":"569","author":"W Wang","year":"2019","unstructured":"Wang W, Green M, Choi JE, Gij\u00f3n M, Kennedy PD, Johnson JK, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270\u201374. https:\/\/doi.org\/10.1038\/s41586-019-1170-y.","journal-title":"Nature"},{"issue":"12","key":"8584_CR186","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/2159-8290.CD-20-0844","volume":"10","author":"SM Fendt","year":"2020","unstructured":"Fendt SM, Frezza C, Erez A. Targeting metabolic plasticity and flexibility dynamics for cancer therapy. Cancer DiscovCancer Discov. 2020;10(12):1797\u2013807. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0844.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"4","key":"8584_CR187","doi-asserted-by":"publisher","first-page":"188749","DOI":"10.1016\/j.bbcan.2022.188749","volume":"1877","author":"S Qin","year":"2022","unstructured":"Qin S, Li B, Ming H, Nice EC, Zou B, Huang C. Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. Biochim et Biophys Acta (BBA) - Rev Cancer. 2022;1877(4):188749. https:\/\/doi.org\/10.1016\/j.bbcan.2022.188749.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"key":"8584_CR188","doi-asserted-by":"publisher","first-page":"1726210","DOI":"10.3389\/fimmu.2025.1726210","volume":"16","author":"Y Wu","year":"2026","unstructured":"Wu Y, Zhang K, Jiang N, Chen Z, Sun X, Zha H, et al. Iron-fueled ferroptosis: a new axis for immunomodulation to overcome cancer drug resistance\u2014from immune microenvironment crosstalk to therapeutic translation. Front Immunol. 2026;16:1726210. https:\/\/doi.org\/10.3389\/fimmu.2025.1726210.","journal-title":"Front Immunol"},{"issue":"6","key":"8584_CR189","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/0008-5472.CAN-14-2103","volume":"75","author":"RH Chisholm","year":"2015","unstructured":"Chisholm RH, Lorenzi T, Lorz A, Larsen AK, de Almeida LND, Escargueil A, et al. Emergence of drug tolerance in cancer cell populations: an evolutionary outcome of selection, nongenetic instability, and stress-induced adaptation. Cancer Res. 2015;75(6):930\u201339. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2103.","journal-title":"Cancer Res"},{"issue":"2","key":"8584_CR190","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. CDR. 2019;2(2):141\u201360. https:\/\/doi.org\/10.20517\/cdr.2019.10.","journal-title":"CDR"},{"issue":"8","key":"8584_CR191","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1517\/13543784.10.8.1571","volume":"10","author":"RJ Williams","year":"2001","unstructured":"Williams RJ. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investigational Drugs. 2001;10(8):1571\u201373. https:\/\/doi.org\/10.1517\/13543784.10.8.1571.","journal-title":"Expert Opin Investigational Drugs"},{"key":"8584_CR192","doi-asserted-by":"publisher","unstructured":"More S, Bonnereau J, Wouters D, Spotbeen X, Karras P, Rizzollo F, et al. Secreted apoe rewires melanoma cell state vulnerability to ferroptosis. Sci Adv. 2024;10(42):eadp 6164. https:\/\/doi.org\/10.1126\/sciadv.adp6164.","DOI":"10.1126\/sciadv.adp6164"},{"issue":"38","key":"8584_CR193","doi-asserted-by":"publisher","first-page":"62726","DOI":"10.18632\/oncotarget.10911","volume":"7","author":"M Tarrado-Castellarnau","year":"2016","unstructured":"Tarrado-Castellarnau M, de Atauri P, Cascante M. Oncogenic regulation of tumor metabolic reprogramming. Oncotarget. 2016;7(38):62726\u201353. https:\/\/doi.org\/10.18632\/oncotarget.10911.","journal-title":"Oncotarget"},{"key":"8584_CR194","doi-asserted-by":"publisher","unstructured":"Damiani C, Colombo R, Gaglio D, Mastroianni F, Pescini D, Westerhoff HV, et al. A metabolic core model elucidates how enhanced utilization of glucose and glutamine, with enhanced glutamine-dependent lactate production, promotes cancer cell growth: the WarburQ effect. PLoS Comput Biol. 2017;13(9):e1005758. https:\/\/doi.org\/10.1371\/journal.pcbi.1005758.","DOI":"10.1371\/journal.pcbi.1005758"},{"issue":"7485","key":"8584_CR195","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nature12946","volume":"505","author":"Y Wan","year":"2014","unstructured":"Wan Y, Qu K, Zhang QC, Flynn RA, Manor O, Ouyang Z, et al. Landscape and variation of RNA secondary structure across the human transcriptome. Nature. 2014;505(7485):706\u201309. https:\/\/doi.org\/10.1038\/nature12946.","journal-title":"Nature"},{"issue":"47","key":"8584_CR196","doi-asserted-by":"publisher","first-page":"49064","DOI":"10.1074\/jbc.M407715200","volume":"279","author":"FL Muller","year":"2004","unstructured":"Muller FL, Liu Y, Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J Biol Chem. 2004;279(47):49064\u201373. https:\/\/doi.org\/10.1074\/jbc.M407715200.","journal-title":"J Biol Chem"},{"issue":"36","key":"8584_CR197","doi-asserted-by":"publisher","first-page":"14804","DOI":"10.1074\/jbc.M117.788901","volume":"292","author":"T Sakamoto","year":"2017","unstructured":"Sakamoto T, Imai H. Hydrogen peroxide produced by superoxide dismutase SOD-2 activates sperm in caenorhabditis elegans. J Biol Chem. 2017;292(36):14804\u201313. https:\/\/doi.org\/10.1074\/jbc.M117.788901.","journal-title":"J Biol Chem"},{"issue":"2","key":"8584_CR198","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.molcel.2015.06.011","volume":"59","author":"M Gao","year":"2015","unstructured":"Gao M, Monian P, Quadri N, Ramasamy R, Jiang X. Glutaminolysis and transferrin regulate ferroptosis. Mol Cell. 2015;59(2):298\u2013308. https:\/\/doi.org\/10.1016\/j.molcel.2015.06.011.","journal-title":"Mol Cell"},{"key":"8584_CR199","doi-asserted-by":"publisher","unstructured":"Yao X, Li W, Fang D, Xiao C, Wu X, Li M, et al. Emerging roles of energy metabolism in ferroptosis regulation of tumor cells. Adv Sci. 2021;8(22):e2100997. https:\/\/doi.org\/10.1002\/advs.202100997.","DOI":"10.1002\/advs.202100997"},{"key":"8584_CR200","doi-asserted-by":"publisher","first-page":"101136","DOI":"10.1016\/j.neo.2025.101136","volume":"61","author":"H Choi","year":"2025","unstructured":"Choi H, Gupta M, Sengupta A, Furth EE, Hensley C, Weljie AM, et al. Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export. Neoplasia. 2025;61:101136. https:\/\/doi.org\/10.1016\/j.neo.2025.101136.","journal-title":"Neoplasia"},{"issue":"6","key":"8584_CR201","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/biology12060864","volume":"12","author":"F Chen","year":"2023","unstructured":"Chen F, Kang R, Liu J, Tang D. The ACSL4 network regulates cell death and autophagy in diseases. Biol (Basel). 2023;12(6):864. https:\/\/doi.org\/10.3390\/biology12060864.","journal-title":"Biol (Basel)"},{"issue":"7","key":"8584_CR202","doi-asserted-by":"publisher","first-page":"110240","DOI":"10.1016\/j.jbc.2025.110240","volume":"301","author":"BD Strahl","year":"2025","unstructured":"Strahl BD, Wang GG. Written in chromatin: the enduring legacy of C. David Allis. J Biol Chem. 2025;301(7):110240. https:\/\/doi.org\/10.1016\/j.jbc.2025.110240.","journal-title":"J Biol Chem"},{"issue":"3","key":"8584_CR203","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/MOL.0000000000000820","volume":"33","author":"L Lagrost","year":"2022","unstructured":"Lagrost L, Masson D. The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease. Curr Opin Lipidol. 2022;33(3):193\u201398. https:\/\/doi.org\/10.1097\/MOL.0000000000000820.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"8584_CR204","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-022-01090-z","volume":"7","author":"XH Ma","year":"2022","unstructured":"Ma XH, Liu JHZ, Liu CY, Sun WY, Duan WJ, Wang G, et al. ALOX15-launched PUFA-phospholipids peroxidation increases the susceptibility of ferroptosis in ischemia-induced myocardial damage. Sig Transduct Target Ther. 2022;7(1):288. https:\/\/doi.org\/10.1038\/s41392-022-01090-z.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"8584_CR205","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/s41467-019-09277-9","volume":"10","author":"Y Zou","year":"2019","unstructured":"Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nat Commun. 2019;10(1):1617. https:\/\/doi.org\/10.1038\/s41467-019-09277-9.","journal-title":"Nat Commun"},{"key":"8584_CR206","doi-asserted-by":"publisher","first-page":"1229710","DOI":"10.3389\/fmolb.2023.1229710","volume":"10","author":"CJ Cardona","year":"2023","unstructured":"Cardona CJ, Montgomery MR. Iron regulatory proteins: players or pawns in ferroptosis and cancer? Front Mol Biosci. 2023;10:1229710. https:\/\/doi.org\/10.3389\/fmolb.2023.1229710.","journal-title":"Front Mol Biosci"},{"key":"8584_CR207","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fphar.2014.00124","volume":"5","author":"DL Zhang","year":"2014","unstructured":"Zhang DL, Ghosh MC, Rouault TA. The physiological functions of iron regulatory proteins in iron homeostasis - an update. Front Pharmacol. 2014;5:124. https:\/\/doi.org\/10.3389\/fphar.2014.00124.","journal-title":"Front Pharmacol"},{"issue":"8","key":"8584_CR208","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1080\/15548627.2016.1187366","volume":"12","author":"W Hou","year":"2016","unstructured":"Hou W, Xie Y, Song X, Sun X, Lotze MT, Zeh HJ 3rd, et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy. 2016;12(8):1425\u201328. https:\/\/doi.org\/10.1080\/15548627.2016.1187366.","journal-title":"Autophagy"},{"issue":"1","key":"8584_CR209","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41698-017-0007-0","volume":"1","author":"DS Neel","year":"2017","unstructured":"Neel DS, Bivona TG. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. Npj Precis Onc. 2017;1(1):1. https:\/\/doi.org\/10.1038\/s41698-017-0007-0.","journal-title":"Npj Precis Onc"},{"issue":"4","key":"8584_CR210","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ccell.2022.02.003","volume":"40","author":"P Liao","year":"2022","unstructured":"Liao P, Wang W, Wang W, Kryczek I, Li X, Bian Y, et al. CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 2022;40(4):365\u201378.e6. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.003.","journal-title":"Cancer Cell"},{"issue":"10","key":"8584_CR211","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1158\/1078-0432.CCR-07-2248","volume":"14","author":"JA Engelman","year":"2008","unstructured":"Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non\u2013small cell lung cancer. Clin Cancer Res. 2008;14(10):2895\u201399. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-2248.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"8584_CR212","doi-asserted-by":"publisher","first-page":"7821","DOI":"10.7150\/thno.78572","volume":"12","author":"X Wei","year":"2022","unstructured":"Wei X, Wang J, Liang M, Song M. Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. Theranostics. 2022;12(18):7821\u201352. https:\/\/doi.org\/10.7150\/thno.78572.","journal-title":"Theranostics"},{"issue":"1","key":"8584_CR213","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s40820-025-01862-6","volume":"18","author":"X Wei","year":"2026","unstructured":"Wei X, Jiang Y, Chenwu F, Li Z, Wan J, Li Z, et al. Synergistic ferroptosis\u2013immunotherapy nanoplatforms: multidimensional engineering for tumor microenvironment remodeling and therapeutic optimization. Nano-Micro Lett. 2026;18(1):56. https:\/\/doi.org\/10.1007\/s40820-025-01862-6.","journal-title":"Nano-Micro Lett"},{"issue":"1","key":"8584_CR214","doi-asserted-by":"publisher","first-page":"7965","DOI":"10.1038\/s41467-022-35707-2","volume":"13","author":"Z Lin","year":"2022","unstructured":"Lin Z, Liu J, Long F, Kang R, Kroemer G, Tang D, et al. The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis. Nat Commun. 2022;13(1):7965. https:\/\/doi.org\/10.1038\/s41467-022-35707-2.","journal-title":"Nat Commun"},{"issue":"7","key":"8584_CR215","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/cells11071113","volume":"11","author":"J Taylor-Papadimitriou","year":"2022","unstructured":"Taylor-Papadimitriou J, Burchell JM. Histone methylases and demethylases regulating antagonistic methyl marks: changes occurring in cancer. Cells. 2022;11(7):1113. https:\/\/doi.org\/10.3390\/cells11071113.","journal-title":"Cells"},{"issue":"7","key":"8584_CR216","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","volume":"12","author":"M Vinogradova","year":"2016","unstructured":"Vinogradova M, Gehling VS, Gustafson A, Arora S, Tindell CA, Wilson C, et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nat Chem Biol. 2016;12(7):531\u201338. https:\/\/doi.org\/10.1038\/nchembio.2085.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"8584_CR217","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/BS9.0000000000000073","volume":"3","author":"Q Li","year":"2021","unstructured":"Li Q, Pan S, Xie T, Liu H. MYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategies. Blood Sci. 2021;3(3):65\u201370. https:\/\/doi.org\/10.1097\/BS9.0000000000000073.","journal-title":"Blood Sci"},{"issue":"7","key":"8584_CR218","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1182\/blood-2013-08-522698","volume":"123","author":"JE Roderick","year":"2014","unstructured":"Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, et al. C-myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014;123(7):1040\u201350. https:\/\/doi.org\/10.1182\/blood-2013-08-522698.","journal-title":"Blood"},{"issue":"5","key":"8584_CR219","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042.","journal-title":"Cell"},{"issue":"7784","key":"8584_CR220","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575(7784):693\u201398. https:\/\/doi.org\/10.1038\/s41586-019-1707-0.","journal-title":"Nature"},{"key":"8584_CR221","doi-asserted-by":"publisher","unstructured":"Anandhan A, Dodson M, Shakya A, Chen J, Liu P, Wei Y, et al. NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8. Sci Adv. 2023;9(5):eade 9585. https:\/\/doi.org\/10.1126\/sciadv.ade9585.","DOI":"10.1126\/sciadv.ade9585"},{"key":"8584_CR222","doi-asserted-by":"publisher","first-page":"1701249","DOI":"10.3389\/fonc.2025.1701249","volume":"15","author":"R Tunc","year":"2025","unstructured":"Tunc R, Ates I, Y\u0131lmaz B, Medoro A, Davinelli S, Suzen S, et al. Modulating Nrf2 to control lipid peroxidation and ferroptosis: implications for cancer management. Front Oncol. 2025;15:1701249. https:\/\/doi.org\/10.3389\/fonc.2025.1701249.","journal-title":"Front Oncol"},{"issue":"7823","key":"8584_CR223","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","volume":"585","author":"JM Ubellacker","year":"2020","unstructured":"Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585(7823):113\u201318. https:\/\/doi.org\/10.1038\/s41586-020-2623-z.","journal-title":"Nature"},{"issue":"1","key":"8584_CR224","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15698\/cst2020.01.208","volume":"4","author":"ZG Liu","year":"2020","unstructured":"Liu ZG, Jiao D. Necroptosis, tumor necrosis and tumorigenesis. CST. 2020;4(1):1\u20138. https:\/\/doi.org\/10.15698\/cst2020.01.208.","journal-title":"CST"},{"key":"8584_CR225","doi-asserted-by":"publisher","first-page":"1629620","DOI":"10.3389\/fimmu.2025.1629620","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan Z, Liu F. Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives. Front. Immunol. 2025;16:1629620. https:\/\/doi.org\/10.3389\/fimmu.2025.1629620.","journal-title":"Front. Immunol"},{"key":"8584_CR226","doi-asserted-by":"publisher","unstructured":"Wang JL, Hua SN, Bao HJ, Yuan J, Zhao Y, Chen S. Pyroptosis and inflammasomes in cancer and inflammation. MedComm (2020). 2023;4(5):e374. https:\/\/doi.org\/10.1002\/mco2.374.","DOI":"10.1002\/mco2.374"},{"issue":"7338","key":"8584_CR227","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/nature09852","volume":"471","author":"A Oberst","year":"2011","unstructured":"Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C, et al. Catalytic activity of the caspase-8\u2013FLIPL complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363\u201367. https:\/\/doi.org\/10.1038\/nature09852.","journal-title":"Nature"},{"issue":"7338","key":"8584_CR228","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/nature09857","volume":"471","author":"WJ Kaiser","year":"2011","unstructured":"Kaiser WJ, Upton JW, Long AB, Livingston-Rosanoff D, Daley-Bauer LP, Hakem R, et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature. 2011;471(7338):368\u201372. https:\/\/doi.org\/10.1038\/nature09857.","journal-title":"Nature"},{"key":"8584_CR229","doi-asserted-by":"publisher","unstructured":"Rogers C, Fernandes-Alnemri T, Mayes L, Alnemri D, Cingolani G, Alnemri ES. Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic\/pyroptotic cell death. Nat Commun. 2017;8(1). https:\/\/doi.org\/10.1038\/ncomms14128.","DOI":"10.1038\/ncomms14128"},{"issue":"10","key":"8584_CR230","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41556-020-0575-z","volume":"22","author":"J Hou","year":"2020","unstructured":"Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, et al. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020;22(10):1264\u201375. https:\/\/doi.org\/10.1038\/s41556-020-0575-z.","journal-title":"Nat Cell Biol"},{"issue":"13","key":"8584_CR231","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.3390\/ijms21134576","volume":"21","author":"AM Czarnecka","year":"2020","unstructured":"Czarnecka AM, Bartnik E, Fiedorowicz M, Rutkowski P. Targeted therapy in melanoma and mechanisms of resistance. IJMS. 2020;21(13):4576. https:\/\/doi.org\/10.3390\/ijms21134576.","journal-title":"IJMS"},{"issue":"1","key":"8584_CR232","doi-asserted-by":"publisher","first-page":"109774","DOI":"10.1016\/j.celrep.2021.109774","volume":"37","author":"F Kuonen","year":"2021","unstructured":"Kuonen F, Li NY, Haensel D, Patel T, Gaddam S, Yerly L, et al. c-FOS drives reversible basal to squamous cell carcinoma transition. Cell Rep. 2021;37(1):109774. https:\/\/doi.org\/10.1016\/j.celrep.2021.109774.","journal-title":"Cell Rep"},{"issue":"6320","key":"8584_CR233","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.aah4307","volume":"355","author":"P Mu","year":"2017","unstructured":"Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017;355(6320):84\u201388. https:\/\/doi.org\/10.1126\/science.aah4307.","journal-title":"Science"},{"issue":"Pt 3","key":"8584_CR234","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.semcancer.2022.10.002","volume":"86","author":"MP Morgan","year":"2022","unstructured":"Morgan MP, Finnegan E, Das S. The role of transcription factors in the acquisition of the four latest proposed hallmarks of cancer and corresponding enabling characteristics. Semin Cancer Biol. 2022;86(Pt 3):1203\u201315. https:\/\/doi.org\/10.1016\/j.semcancer.2022.10.002.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"8584_CR235","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/03008916231225576","volume":"110","author":"M Ma","year":"2024","unstructured":"Ma M, Zhu Y, Xiao C, Li R, Cao X, Kang R, et al. Novel insights into RB1 in prostate cancer lineage plasticity and drug resistance. Tumori. 2024;110(4):252\u201363. https:\/\/doi.org\/10.1177\/03008916231225576.","journal-title":"Tumori"},{"issue":"53","key":"8584_CR236","doi-asserted-by":"publisher","first-page":"7445","DOI":"10.1038\/sj.onc.1210546","volume":"26","author":"S Julien","year":"2007","unstructured":"Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-\u03baB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007;26(53):7445\u201356. https:\/\/doi.org\/10.1038\/sj.onc.1210546.","journal-title":"Oncogene"},{"issue":"3","key":"8584_CR237","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ncb2029","volume":"12","author":"A Chaudhury","year":"2010","unstructured":"Chaudhury A, Hussey GS, Ray PS, Jin G, Fox PL, Howe PH. TGF-\u03b2-mediated phosphorylation of hnRNP E1 induces EMT via transcript-selective translational induction of Dab2 and ILEI. Nat Cell Biol. 2010;12(3):286\u201393. https:\/\/doi.org\/10.1038\/ncb2029.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"8584_CR238","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.gendis.2022.11.025","volume":"11","author":"EH Maleki","year":"2024","unstructured":"Maleki EH, Bahrami AR, Matin MM. Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance. Genes & Dis. 2024;11(1):189\u2013204. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.025.","journal-title":"Genes & Dis"},{"issue":"7","key":"8584_CR239","doi-asserted-by":"publisher","first-page":"101042831771261","DOI":"10.1177\/1010428317712617","volume":"39","author":"Y Song","year":"2017","unstructured":"Song Y, Li ZX, Liu X, Wang R, Li LW, Zhang Q. The Wnt\/\u03b2-catenin and PI3K\/Akt signaling pathways promote EMT in gastric cancer by epigenetic regulation via H3 lysine 27 acetylation. Tumour Biol. 2017;39(7):1010428317712617. https:\/\/doi.org\/10.1177\/1010428317712617.","journal-title":"Tumour Biol"},{"issue":"4","key":"8584_CR240","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/jcm5040041","volume":"5","author":"J Zhang","year":"2016","unstructured":"Zhang J, Tian XJ, Xing J. Signal transduction pathways of EMT induced by TGF-\u03b2, SHH, and WNT and their crosstalks. JCM. 2016;5(4):41. https:\/\/doi.org\/10.3390\/jcm5040041.","journal-title":"JCM"},{"issue":"4","key":"8584_CR241","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1042\/EBC20220016","volume":"66","author":"M Katoh","year":"2022","unstructured":"Katoh M, Katoh M. WNT signaling and cancer stemness. Essays Biochem. 2022;66(4):319\u201331. https:\/\/doi.org\/10.1042\/EBC20220016.","journal-title":"Essays Biochem"},{"issue":"1","key":"8584_CR242","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41389-023-00452-8","volume":"12","author":"S Diazzi","year":"2023","unstructured":"Diazzi S, Tartare-Deckert S, Deckert M. The Mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance. Oncogenesis. 2023;12(1):7. https:\/\/doi.org\/10.1038\/s41389-023-00452-8.","journal-title":"Oncogenesis"},{"key":"8584_CR243","doi-asserted-by":"publisher","unstructured":"Safa AR. Resistance to drugs and cell death in cancer stem cells (CSCs). J Transl Sci. 2020;6(3). https:\/\/doi.org\/10.15761\/JTS.1000341.","DOI":"10.15761\/JTS.1000341"},{"issue":"39","key":"8584_CR244","doi-asserted-by":"publisher","first-page":"14228","DOI":"10.1073\/pnas.0400067101","volume":"101","author":"C Hirschmann-Jax","year":"2004","unstructured":"Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, et al. A distinct \u201cside population\u201d of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101(39):14228\u201333. https:\/\/doi.org\/10.1073\/pnas.0400067101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"18","key":"8584_CR245","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821\u201328.","journal-title":"Cancer Res"},{"issue":"22","key":"8584_CR246","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.1039\/D0CS00379D","volume":"49","author":"J Han","year":"2020","unstructured":"Han J, Won M, Kim JH, Jung E, Min K, Jangili P, et al. Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective. Chem Soc Rev. 2020;49(22):7856\u201378. https:\/\/doi.org\/10.1039\/D0CS00379D.","journal-title":"Chem Soc Rev"},{"issue":"4","key":"8584_CR247","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas RA. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323. https:\/\/doi.org\/10.1016\/j.cell.2017.01.017.","journal-title":"Cell"},{"key":"8584_CR248","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.phrs.2018.10.011","volume":"137","author":"SR Martins-Neves","year":"2018","unstructured":"Martins-Neves SR, Cleton-Jansen AM, Gomes CMF. Therapy-induced enrichment of cancer stem-like cells in solid human tumors: where do we stand? Pharmacological Res. 2018;137:193\u2013204. https:\/\/doi.org\/10.1016\/j.phrs.2018.10.011.","journal-title":"Pharmacological Res"},{"issue":"10","key":"8584_CR249","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc3599","volume":"13","author":"C Holohan","year":"2013","unstructured":"Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714\u201326. https:\/\/doi.org\/10.1038\/nrc3599.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"8584_CR250","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1016\/j.celrep.2017.02.001","volume":"18","author":"H Lu","year":"2017","unstructured":"Lu H, Chen I, Shimoda LA, Park Y, Zhang C, Tran L, et al. Chemotherapy-induced Ca2+ release stimulates breast cancer stem cell enrichment. Cell Rep. 2017;18(8):1946\u201357. https:\/\/doi.org\/10.1016\/j.celrep.2017.02.001.","journal-title":"Cell Rep"},{"issue":"4","key":"8584_CR251","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.cell.2011.07.026","volume":"146","author":"PB Gupta","year":"2011","unstructured":"Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011;146(4):633\u201344. https:\/\/doi.org\/10.1016\/j.cell.2011.07.026.","journal-title":"Cell"},{"issue":"4","key":"8584_CR252","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1038\/ng.2913","volume":"46","author":"B Knoechel","year":"2014","unstructured":"Knoechel B, Roderick JE, Williamson KE, Zhu J, Lohr JG, Cotton MJ, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364\u201370. https:\/\/doi.org\/10.1038\/ng.2913.","journal-title":"Nat Genet"},{"issue":"2","key":"8584_CR253","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.stem.2016.11.003","volume":"20","author":"BB Liau","year":"2017","unstructured":"Liau BB, Sievers C, Donohue LK, Gillespie SM, Flavahan WA, Miller TE, et al. Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance. Cell STEM Cell. 2017;20(2):233\u201346.e7. https:\/\/doi.org\/10.1016\/j.stem.2016.11.003.","journal-title":"Cell STEM Cell"},{"issue":"8","key":"8584_CR254","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.celrep.2017.04.077","volume":"19","author":"MP Dalvi","year":"2017","unstructured":"Dalvi MP, Wang L, Zhong R, Kollipara RK, Park H, Bayo J, et al. Taxane-platin-resistant lung cancers Co-develop hypersensitivity to JumonjiC demethylase inhibitors. Cell Rep. 2017;19(8):1669\u201384. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.077.","journal-title":"Cell Rep"},{"issue":"2","key":"8584_CR255","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","volume":"32","author":"GD Guler","year":"2017","unstructured":"Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, et al. Repression of stress-induced LINE-1 expression protects cancer cell subpopulations from lethal drug exposure. Cancer Cell. 2017;32(2):221\u201337.e13. https:\/\/doi.org\/10.1016\/j.ccell.2017.07.002.","journal-title":"Cancer Cell"},{"issue":"1","key":"8584_CR256","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1038\/s41467-018-05729-w","volume":"9","author":"T Risom","year":"2018","unstructured":"Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, et al. Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun. 2018;9(1):3815. https:\/\/doi.org\/10.1038\/s41467-018-05729-w.","journal-title":"Nat Commun"},{"issue":"1","key":"8584_CR257","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","volume":"11","author":"C Calabrese","year":"2007","unstructured":"Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007;11(1):69\u201382. https:\/\/doi.org\/10.1016\/j.ccr.2006.11.020.","journal-title":"Cancer Cell"},{"issue":"2","key":"8584_CR258","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.stem.2010.01.001","volume":"6","author":"N Charles","year":"2010","unstructured":"Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell. 2010;6(2):141\u201352. https:\/\/doi.org\/10.1016\/j.stem.2010.01.001.","journal-title":"Cell STEM Cell"},{"issue":"5","key":"8584_CR259","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ncb2048","volume":"12","author":"L Vermeulen","year":"2010","unstructured":"Vermeulen L, De Sousa F, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468\u201376. https:\/\/doi.org\/10.1038\/ncb2048.","journal-title":"Nat Cell Biol"},{"issue":"3","key":"8584_CR260","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.stem.2014.01.009","volume":"14","author":"M Todaro","year":"2014","unstructured":"Todaro M, Gaggianesi M, Catalano V, Benfante A, Iovino F, Biffoni M, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014;14(3):342\u201356. https:\/\/doi.org\/10.1016\/j.stem.2014.01.009.","journal-title":"Cell STEM Cell"},{"issue":"11","key":"8584_CR261","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ncb3041","volume":"16","author":"H Lu","year":"2014","unstructured":"Lu H, Clauser KR, Tam WL, Fr\u00f6se J, Ye X, Eaton EN, et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol. 2014;16(11):1105\u201317. https:\/\/doi.org\/10.1038\/ncb3041.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"8584_CR262","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1158\/0008-5472.CAN-16-2129","volume":"77","author":"P Sansone","year":"2017","unstructured":"Sansone P, Berishaj M, Rajasekhar VK, Ceccarelli C, Chang Q, Strillacci A, et al. Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles. Cancer Res. 2017;77(8):1927\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2129.","journal-title":"Cancer Res"},{"issue":"2","key":"8584_CR263","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41556-018-0267-0","volume":"21","author":"P Carlson","year":"2019","unstructured":"Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol. 2019;21(2):238\u201350. https:\/\/doi.org\/10.1038\/s41556-018-0267-0.","journal-title":"Nat Cell Biol"},{"issue":"6409","key":"8584_CR264","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1126\/science.aav0191","volume":"361","author":"JA Aguirre-Ghiso","year":"2018","unstructured":"Aguirre-Ghiso JA. How dormant cancer persists and reawakens. Science. 2018;361(6409):1314\u201315. https:\/\/doi.org\/10.1126\/science.aav0191.","journal-title":"Science"},{"issue":"11","key":"8584_CR265","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41556-018-0214-0","volume":"20","author":"ET Goddard","year":"2018","unstructured":"Goddard ET, Bozic I, Riddell SR, Ghajar CM. Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 2018;20(11):1240\u201349. https:\/\/doi.org\/10.1038\/s41556-018-0214-0.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"8584_CR266","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/ncb3465","volume":"19","author":"G Fluegen","year":"2017","unstructured":"Fluegen G, Avivar-Valderas A, Wang Y, Padgen MR, Williams JK, Nobre AR, et al. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments. Nat Cell Biol. 2017;19(2):120\u201332. https:\/\/doi.org\/10.1038\/ncb3465.","journal-title":"Nat Cell Biol"},{"issue":"7","key":"8584_CR267","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10585-009-9260-0","volume":"26","author":"JL Dembinski","year":"2009","unstructured":"Dembinski JL, Krauss S. Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma. Clin Exp Metastasis. 2009;26(7):611\u201323. https:\/\/doi.org\/10.1007\/s10585-009-9260-0.","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"8584_CR268","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1158\/0008-5472.CAN-12-2067","volume":"73","author":"WC Lin","year":"2013","unstructured":"Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, et al. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. Cancer Res. 2013;73(6):1821\u201330. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2067.","journal-title":"Cancer Res"},{"issue":"20","key":"8584_CR269","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/onc.2016.431","volume":"36","author":"H Endo","year":"2017","unstructured":"Endo H, Okami J, Okuyama H, Nishizawa Y, Imamura F, Inoue M. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations. Oncogene. 2017;36(20):2824\u201334. https:\/\/doi.org\/10.1038\/onc.2016.431.","journal-title":"Oncogene"},{"issue":"6","key":"8584_CR270","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/ncponc1110","volume":"5","author":"A Trumpp","year":"2008","unstructured":"Trumpp A, Wiestler OD. Mechanisms of disease: cancer stem cells\u2014targeting the evil twin. Nat Rev Clin Oncol. 2008;5(6):337\u201347. https:\/\/doi.org\/10.1038\/ncponc1110.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"8584_CR271","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/sj.bjc.6603024","volume":"94","author":"RM Glasspool","year":"2006","unstructured":"Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006;94(8):1087\u201392. https:\/\/doi.org\/10.1038\/sj.bjc.6603024.","journal-title":"Br J Cancer"},{"issue":"1","key":"8584_CR272","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/annonc\/mdh006","volume":"15","author":"T Kurata","year":"2004","unstructured":"Kurata T, Tamura K, Kaneda H, Nogami T, Uejima H, Asai Go G, et al. Effect of re-treatment with gefitinib (\u2018iressa\u2019, ZD1839) after acquisition of resistance. Ann Oncol. 2004;15(1):173\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdh006.","journal-title":"Ann Oncol"},{"issue":"2","key":"8584_CR273","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3727\/096504005775082020","volume":"15","author":"S Yano","year":"2005","unstructured":"Yano S, Nakataki E, Ohtsuka S, Inayama M, Tomimoto H, Edakuni N, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol Res. 2005;15(2):107\u201311. https:\/\/doi.org\/10.3727\/096504005775082020.","journal-title":"Oncol Res"},{"issue":"1","key":"8584_CR274","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/A:1008389706725","volume":"12","author":"S Cara","year":"2001","unstructured":"Cara S, Tannock IF. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann Oncol. 2001;12(1):23\u201327. https:\/\/doi.org\/10.1023\/A:1008389706725.","journal-title":"Ann Oncol"},{"issue":"3","key":"8584_CR275","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","volume":"12","author":"ED Lagadinou","year":"2013","unstructured":"Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell STEM Cell. 2013;12(3):329\u201341. https:\/\/doi.org\/10.1016\/j.stem.2012.12.013.","journal-title":"Cell STEM Cell"},{"issue":"1","key":"8584_CR276","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2009.12.007","volume":"140","author":"S Pece","year":"2010","unstructured":"Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):62\u201373. https:\/\/doi.org\/10.1016\/j.cell.2009.12.007.","journal-title":"Cell"},{"issue":"10","key":"8584_CR277","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23(10):1124\u201334. https:\/\/doi.org\/10.1038\/nm.4409.","journal-title":"Nat Med"},{"issue":"4","key":"8584_CR278","doi-asserted-by":"publisher","first-page":"165339","DOI":"10.1016\/j.bbadis.2018.11.015","volume":"1866","author":"MR Makena","year":"2020","unstructured":"Makena MR, Ranjan A, Thirumala V, Reddy AP. Cancer stem cells: road to therapeutic resistance and strategies to overcome resistance. Biochim Et Biophys Acta (BBA) - Mol Basis Disease. 2020;1866(4):165339. https:\/\/doi.org\/10.1016\/j.bbadis.2018.11.015.","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"issue":"3","key":"8584_CR279","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.stem.2014.02.006","volume":"14","author":"A Kreso","year":"2014","unstructured":"Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275\u201391. https:\/\/doi.org\/10.1016\/j.stem.2014.02.006.","journal-title":"Cell STEM Cell"},{"issue":"6","key":"8584_CR280","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.stem.2014.11.012","volume":"15","author":"A Zeuner","year":"2014","unstructured":"Zeuner A, Todaro M, Stassi G, De Maria R. Colorectal cancer stem cells: from the crypt to the clinic. Cell Stem Cell. 2014;15(6):692\u2013705. https:\/\/doi.org\/10.1016\/j.stem.2014.11.012.","journal-title":"Cell STEM Cell"},{"issue":"10","key":"8584_CR281","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/cdd.2015.19","volume":"22","author":"F Francescangeli","year":"2015","unstructured":"Francescangeli F, Contavalli P, De Angelis ML, Baiocchi M, Gambara G, Pagliuca A, et al. Dynamic regulation of the cancer stem cell compartment by cripto-1 in colorectal cancer. Cell Death Differ. 2015;22(10):1700\u201313. https:\/\/doi.org\/10.1038\/cdd.2015.19.","journal-title":"Cell Death Differ"},{"key":"8584_CR282","doi-asserted-by":"publisher","unstructured":"Bragado P, Estrada Y, Sosa MS, Avivar-Valderas A, Cannan D, Genden E, et al. Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS One. 2012;7(1):e29974. https:\/\/doi.org\/10.1371\/journal.pone.0029974.","DOI":"10.1371\/journal.pone.0029974"},{"issue":"4","key":"8584_CR283","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","volume":"141","author":"A Roesch","year":"2010","unstructured":"Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141(4):583\u201394. https:\/\/doi.org\/10.1016\/j.cell.2010.04.020.","journal-title":"Cell"},{"issue":"12","key":"8584_CR284","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1038\/cdd.2014.105","volume":"21","author":"A Zeuner","year":"2014","unstructured":"Zeuner A, Francescangeli F, Contavalli P, Zapparelli G, Apuzzo T, Eramo A, et al. Elimination of quiescent\/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death Differ. 2014;21(12):1877\u201388. https:\/\/doi.org\/10.1038\/cdd.2014.105.","journal-title":"Cell Death Differ"},{"issue":"6","key":"8584_CR285","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ccell.2016.11.002","volume":"30","author":"S Ebinger","year":"2016","unstructured":"Ebinger S, \u00d6zdemir EZ, Ziegenhain C, Tiedt S, Castro Alves C, Grunert M, et al. Characterization of rare, dormant, and therapy-resistant cells in acute lymphoblastic leukemia. Cancer Cell. 2016;30(6):849\u201362. https:\/\/doi.org\/10.1016\/j.ccell.2016.11.002.","journal-title":"Cancer Cell"},{"issue":"7784","key":"8584_CR286","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/s41586-019-1705-2","volume":"575","author":"K Bersuker","year":"2019","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688\u201392. https:\/\/doi.org\/10.1038\/s41586-019-1705-2.","journal-title":"Nature"},{"issue":"4","key":"8584_CR287","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nm1388","volume":"12","author":"K Ito","year":"2006","unstructured":"Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, Miyamoto K, et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med. 2006;12(4):446\u201351. https:\/\/doi.org\/10.1038\/nm1388.","journal-title":"Nat Med"},{"issue":"7524","key":"8584_CR288","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, Pettazzoni P, Lyssiotis CA, Ying H, S\u00e1nchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514(7524):628\u201332. https:\/\/doi.org\/10.1038\/nature13611.","journal-title":"Nature"},{"issue":"1","key":"8584_CR289","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11033-025-10748-0","volume":"52","author":"EW Tan","year":"2025","unstructured":"Tan EW, Singh SK, Dua K, Gupta G, Lee WL, Wong RSY, et al. Cancer stem cells: mitochondria signalling pathway and strategies for therapeutic interventions. Mol Biol Rep. 2025;52(1):671. https:\/\/doi.org\/10.1007\/s11033-025-10748-0.","journal-title":"Mol Biol Rep"},{"key":"8584_CR290","doi-asserted-by":"publisher","unstructured":"Zeuner A. The secret life of quiescent cancer stem cells. Mol Cellular Oncol. 2015;2(1):e968067. https:\/\/doi.org\/10.4161\/23723548.2014.968067.","DOI":"10.4161\/23723548.2014.968067"},{"issue":"27","key":"8584_CR291","doi-asserted-by":"publisher","first-page":"24061","DOI":"10.18632\/oncotarget.4448","volume":"6","author":"E Giannoni","year":"2015","unstructured":"Giannoni E, Taddei ML, Morandi A, Comito G, Calvani M, Bianchini F, et al. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread. Oncotarget. 2015;6(27):24061\u201374. https:\/\/doi.org\/10.18632\/oncotarget.4448.","journal-title":"Oncotarget"},{"issue":"38","key":"8584_CR292","doi-asserted-by":"publisher","first-page":"61890","DOI":"10.18632\/oncotarget.11301","volume":"7","author":"L Ippolito","year":"2016","unstructured":"Ippolito L, Marini A, Cavallini L, Morandi A, Pietrovito L, Pintus G, et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells. Oncotarget. 2016;7(38):61890\u2013904. https:\/\/doi.org\/10.18632\/oncotarget.11301.","journal-title":"Oncotarget"},{"issue":"9","key":"8584_CR293","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/cdd.2016.39","volume":"23","author":"DS Matassa","year":"2016","unstructured":"Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23(9):1542\u201354. https:\/\/doi.org\/10.1038\/cdd.2016.39.","journal-title":"Cell Death Differ"},{"issue":"1","key":"8584_CR294","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/0008-5472.CAN-11-1674","volume":"72","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 2012;72(1):304\u201314. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1674.","journal-title":"Cancer Res"},{"issue":"6","key":"8584_CR295","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-15-2038","volume":"76","author":"M Bacci","year":"2016","unstructured":"Bacci M, Giannoni E, Fearns A, Ribas R, Gao Q, Taddei ML, et al. miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors. Cancer Res. 2016;76(6):1615\u201326. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2038.","journal-title":"Cancer Res"},{"issue":"7","key":"8584_CR296","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/bjc.2016.26","volume":"114","author":"LE Botzer","year":"2016","unstructured":"Botzer LE, Maman S, Sagi-Assif O, Meshel T, Nevo I, Yron I, et al. Hexokinase 2 is a determinant of neuroblastoma metastasis. Br J Cancer. 2016;114(7):759\u201366. https:\/\/doi.org\/10.1038\/bjc.2016.26.","journal-title":"Br J Cancer"},{"key":"8584_CR297","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/242437","volume":"2015","author":"CD Bovenzi","year":"2015","unstructured":"Bovenzi CD, Hamilton J, Tassone P, Johnson J, Cognetti DM, Luginbuhl A, et al. Prognostic indications of elevated MCT4 and CD147 across cancer types: a meta-analysis. Biomed Res Int. 2015;2015:1\u201314. https:\/\/doi.org\/10.1155\/2015\/242437.","journal-title":"Biomed Res Int"},{"issue":"1","key":"8584_CR298","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2014.07.050","volume":"451","author":"J Doyen","year":"2014","unstructured":"Doyen J, Trastour C, Ettore F, Peyrottes I, Toussant N, Gal J, et al. Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome. Biochem Bioph Res Co. 2014;451(1):54\u201361. https:\/\/doi.org\/10.1016\/j.bbrc.2014.07.050.","journal-title":"Biochem Bioph Res Co"},{"issue":"5","key":"8584_CR299","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.ccell.2019.03.007","volume":"35","author":"M Elgendy","year":"2019","unstructured":"Elgendy M, Cir\u00f2 M, Hosseini A, Weiszmann J, Mazzarella L, Ferrari E, et al. Combination of hypoglycemia and metformin impairs tumor metabolic plasticity and growth by modulating the PP2A-GSK3\u03b2-MCL-1 axis. Cancer Cell. 2019;35(5):798\u2013815.e5. https:\/\/doi.org\/10.1016\/j.ccell.2019.03.007.","journal-title":"Cancer Cell"},{"issue":"5","key":"8584_CR300","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.3174","volume":"19","author":"F De Sousa","year":"2013","unstructured":"De Sousa F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij Lp, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614\u201318. https:\/\/doi.org\/10.1038\/nm.3174.","journal-title":"Nat Med"},{"issue":"6334","key":"8584_CR301","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1126\/science.aak9510","volume":"356","author":"S Stevanovi\u0107","year":"2017","unstructured":"Stevanovi\u0107 S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356(6334):200\u201305. https:\/\/doi.org\/10.1126\/science.aak9510.","journal-title":"Science"},{"issue":"11","key":"8584_CR302","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrc2256","volume":"7","author":"JA Aguirre-Ghiso","year":"2007","unstructured":"Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007;7(11):834\u201346. https:\/\/doi.org\/10.1038\/nrc2256.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8584_CR303","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cell.2016.02.025","volume":"165","author":"S Malladi","year":"2016","unstructured":"Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell. 2016;165(1):45\u201360. https:\/\/doi.org\/10.1016\/j.cell.2016.02.025.","journal-title":"Cell"},{"issue":"7","key":"8584_CR304","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","volume":"20","author":"TG Phan","year":"2020","unstructured":"Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398\u2013411. https:\/\/doi.org\/10.1038\/s41568-020-0263-0.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"8584_CR305","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807\u201317. https:\/\/doi.org\/10.1038\/ncb2767.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"8584_CR306","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbcan.2016.12.004","volume":"1868","author":"A Morandi","year":"2017","unstructured":"Morandi A, Indraccolo S. Linking metabolic reprogramming to therapy resistance in cancer. Biochim et Biophys Acta (BBA) - Rev Cancer. 2017;1868(1):1\u20136. https:\/\/doi.org\/10.1016\/j.bbcan.2016.12.004.","journal-title":"Biochim et Biophys Acta (BBA) - Rev Cancer"},{"issue":"32","key":"8584_CR307","doi-asserted-by":"publisher","first-page":"14333","DOI":"10.1073\/pnas.1000248107","volume":"107","author":"A Gupta","year":"2010","unstructured":"Gupta A, Roy S, Lazar AJF, Wang WL, McAuliffe JC, Reynoso D, et al. Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA. 2010;107(32):14333\u201338. https:\/\/doi.org\/10.1073\/pnas.1000248107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"8584_CR308","doi-asserted-by":"publisher","first-page":"3917","DOI":"10.1172\/JCI35512","volume":"118","author":"Z Lu","year":"2008","unstructured":"Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, et al. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008;118(12):3917\u201329. https:\/\/doi.org\/10.1172\/JCI35512.","journal-title":"J Clin Invest"},{"issue":"6009","key":"8584_CR309","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1126\/science.1193497","volume":"330","author":"JD Rabinowitz","year":"2010","unstructured":"Rabinowitz JD, White E. Autophagy and metabolism. Science. 2010;330(6009):1344\u201348. https:\/\/doi.org\/10.1126\/science.1193497.","journal-title":"Science"},{"issue":"1","key":"8584_CR310","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/s41467-019-08902-x","volume":"10","author":"J Ou","year":"2019","unstructured":"Ou J, Peng Y, Yang W, Zhang Y, Hao J, Li F, et al. ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via promoting autophagic uracil yield. Nat Commun. 2019;10(1):1078. https:\/\/doi.org\/10.1038\/s41467-019-08902-x.","journal-title":"Nat Commun"},{"key":"8584_CR311","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.12688\/f1000research.12174.1","volume":"6","author":"L Vera-Ramirez","year":"2017","unstructured":"Vera-Ramirez L, Hunter KW. Tumor cell dormancy as an adaptive cell stress response mechanism. F1000Res. 2017;6:2134. https:\/\/doi.org\/10.12688\/f1000research.12174.1.","journal-title":"F1000Res"},{"issue":"1","key":"8584_CR312","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1038\/s41467-018-04070-6","volume":"9","author":"L Vera-Ramirez","year":"2018","unstructured":"Vera-Ramirez L, Vodnala SK, Nini R, Hunter KW, Green JE. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence. Nat Commun. 2018;9(1):1944. https:\/\/doi.org\/10.1038\/s41467-018-04070-6.","journal-title":"Nat Commun"},{"issue":"1","key":"8584_CR313","doi-asserted-by":"publisher","first-page":"10442","DOI":"10.1038\/ncomms10442","volume":"7","author":"P Sansone","year":"2016","unstructured":"Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F, et al. Self-renewal of CD133hi cells by IL6\/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun. 2016;7(1):10442. https:\/\/doi.org\/10.1038\/ncomms10442.","journal-title":"Nat Commun"},{"issue":"5","key":"8584_CR314","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41556-018-0083-6","volume":"20","author":"W Yan","year":"2018","unstructured":"Yan W, Wu X, Zhou W, Fong MY, Cao M, Liu J, et al. Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol. 2018;20(5):597\u2013609. https:\/\/doi.org\/10.1038\/s41556-018-0083-6.","journal-title":"Nat Cell Biol"},{"key":"8584_CR315","doi-asserted-by":"publisher","unstructured":"Kuang R, Jahangiri A, Mascharak S, Nguyen A, Chandra A, Flanigan PM, et al. GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance. JCI Insight. 2017;2(2):e88815. https:\/\/doi.org\/10.1172\/jci.insight.88815.","DOI":"10.1172\/jci.insight.88815"},{"issue":"11","key":"8584_CR316","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.trecan.2016.10.009","volume":"2","author":"X Zhang","year":"2016","unstructured":"Zhang X, De Milito A, Demiroglu-Zergeroglu A, Gullbo J, D\u2019Arcy P, Linder S. Eradicating quiescent tumor cells by targeting mitochondrial bioenergetics. Trends Cancer. 2016;2(11):657\u201363. https:\/\/doi.org\/10.1016\/j.trecan.2016.10.009.","journal-title":"Trends Cancer"},{"issue":"3","key":"8584_CR317","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.molcel.2025.11.013","volume":"86","author":"A Aufschnaiter","year":"2026","unstructured":"Aufschnaiter A, Oh T-J, Oberst A. The landscape of regulated cell death: It\u2019s all downhill from here. Mol Cell. 2026;86(3):553\u201365. https:\/\/doi.org\/10.1016\/j.molcel.2025.11.013.","journal-title":"Mol Cell"},{"issue":"2","key":"8584_CR318","doi-asserted-by":"publisher","first-page":"113860","DOI":"10.1016\/j.yexcr.2023.113860","volume":"433","author":"S Dehghan","year":"2023","unstructured":"Dehghan S, Kheshtchin N, Hassannezhad S, Soleimani M. Cell death classification: a new insight based on molecular mechanisms. Exp Cell Res. 2023;433(2):113860. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113860.","journal-title":"Exp Cell Res"},{"key":"8584_CR319","doi-asserted-by":"publisher","unstructured":"Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0580.","DOI":"10.1001\/jamaoncol.2017.0580"},{"issue":"1","key":"8584_CR320","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/asheducation-2010.1.7","volume":"2010","author":"D Campana","year":"2010","unstructured":"Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2010;2010(1):7\u201312. https:\/\/doi.org\/10.1182\/asheducation-2010.1.7.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"34","key":"8584_CR321","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14694\/EdBook_AM.2014.34.3","volume":"34","author":"L Norton","year":"2014","unstructured":"Norton L. Cancer log-kill revisited. Am Soc Clin Oncol Educ Book. 2014;34(34):3\u20137. https:\/\/doi.org\/10.14694\/EdBook_AM.2014.34.3.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"8584_CR322","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. The Lancet Oncol. 2010;11(11):1029\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(10)70233-3.","journal-title":"The Lancet Oncol"},{"issue":"6","key":"8584_CR323","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. The Lancet Oncol. 2018;19(6):747\u201357. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X.","journal-title":"The Lancet Oncol"},{"issue":"2","key":"8584_CR324","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in Untreated EGFR -Mutated advanced non\u2013small-Cell lung cancer. N Engl J Med. 2018;378(2):113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"issue":"1","key":"8584_CR325","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in Untreated, EGFR-Mutated advanced NSCLC. N Engl J Med. 2020;382(1):41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"issue":"19","key":"8584_CR326","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-11-1468","volume":"17","author":"JE Chaft","year":"2011","unstructured":"Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res. 2011;17(19):6298\u2013303. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1468.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"8584_CR327","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1158\/1078-0432.CCR-07-0560","volume":"13","author":"GJ Riely","year":"2007","unstructured":"Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res. 2007;13(17):5150\u201355. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0560.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8584_CR328","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1038\/s41467-024-47606-9","volume":"15","author":"S Hobor","year":"2024","unstructured":"Hobor S, Al Bakir M, Hiley CT, Skrzypski M, Frankell AM, Bakker B, et al. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling. Nat Commun. 2024;15(1):4871. https:\/\/doi.org\/10.1038\/s41467-024-47606-9.","journal-title":"Nat Commun"},{"issue":"2","key":"8584_CR329","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2214\/AJR.09.4110","volume":"195","author":"M Nishino","year":"2010","unstructured":"Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. Am J Roentgenol. 2010;195(2):281\u201389. https:\/\/doi.org\/10.2214\/AJR.09.4110.","journal-title":"Am J Roentgenol"},{"issue":"3","key":"8584_CR330","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Mulvey HE, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med. 2016;22(3):262\u201369. https:\/\/doi.org\/10.1038\/nm.4040.","journal-title":"Nat Med"},{"issue":"3","key":"8584_CR331","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.immuni.2016.07.016","volume":"45","author":"S Alvarez-Diaz","year":"2016","unstructured":"Alvarez-Diaz S, Dillon CP, Lalaoui N, Tanzer MC, Rodriguez DA, Lin A, et al. The pseudokinase MLKL and the kinase RIPK3 have distinct roles in autoimmune disease Caused by loss of death-receptor-induced apoptosis. Immunity. 2016;45(3):513\u201326. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.016.","journal-title":"Immunity"},{"issue":"7","key":"8584_CR332","doi-asserted-by":"publisher","first-page":"167317","DOI":"10.1016\/j.bbadis.2024.167317","volume":"1870","author":"MA Yapryntseva","year":"2024","unstructured":"Yapryntseva MA, Zhivotovsky B, Gogvadze V. Permeabilization of the outer mitochondrial membrane: mechanisms and consequences. Biochim Et Biophys Acta (BBA) - Mol Basis Disease. 2024;1870(7):167317. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167317.","journal-title":"Biochim Et Biophys Acta (BBA) - Mol Basis Disease"},{"key":"8584_CR333","doi-asserted-by":"publisher","unstructured":"Higuchi M, Williams AF, Stuhlfire AE, Nguyen AH, Gervasio DAG, Turkal CE, et al. FSP1 and histone deacetylases suppress cancer persister cell ferroptosis. Sci Adv. 2026;12(1):eaea 8771. https:\/\/doi.org\/10.1126\/sciadv.aea8771.","DOI":"10.1126\/sciadv.aea8771"},{"issue":"9","key":"8584_CR334","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","volume":"28","author":"JC Soria","year":"2010","unstructured":"Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, Carboplatin, and Bevacizumab in patients with advanced non-squamous non\u2013small-Cell lung cancer. JCO. 2010;28(9):1527\u201333. https:\/\/doi.org\/10.1200\/JCO.2009.25.4847.","journal-title":"JCO"},{"issue":"3","key":"8584_CR335","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/sj.bjc.6605507","volume":"102","author":"T Trarbach","year":"2010","unstructured":"Trarbach T, Moehler M, Heinemann V, K\u00f6hne CH, Przyborek M, Schulz C, et al. Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br J Cancer. 2010;102(3):506\u201312. https:\/\/doi.org\/10.1038\/sj.bjc.6605507.","journal-title":"Br J Cancer"},{"issue":"23","key":"8584_CR336","doi-asserted-by":"publisher","first-page":"5883","DOI":"10.1158\/1078-0432.CCR-10-0631","volume":"16","author":"RS Herbst","year":"2010","unstructured":"Herbst RS, Kurzrock R, Hong DS, Valdivieso M, Hsu CP, Goyal L, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010;16(23):5883\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0631.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8584_CR337","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1412690.","journal-title":"N Engl J Med"},{"issue":"20","key":"8584_CR338","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867\u201376. https:\/\/doi.org\/10.1056\/NEJMoa1408868.","journal-title":"N Engl J Med"},{"issue":"5","key":"8584_CR339","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.cell.2015.01.042","volume":"160","author":"J Montero","year":"2015","unstructured":"Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977\u201389. https:\/\/doi.org\/10.1016\/j.cell.2015.01.042.","journal-title":"Cell"},{"issue":"28","key":"8584_CR340","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1200\/JCO.2016.66.7162","volume":"34","author":"GR Oxnard","year":"2016","unstructured":"Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. Association between plasma genotyping and outcomes of treatment with Osimertinib (AZD9291) in advanced non\u2013small-Cell lung cancer. J Clin Oncol. 2016;34(28):3375\u201382. https:\/\/doi.org\/10.1200\/JCO.2016.66.7162.","journal-title":"JCO"},{"issue":"7655","key":"8584_CR341","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446\u201351. https:\/\/doi.org\/10.1038\/nature22364.","journal-title":"Nature"},{"key":"8584_CR342","doi-asserted-by":"publisher","unstructured":"Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. https:\/\/doi.org\/10.1126\/scitranslmed.aaf6219.","DOI":"10.1126\/scitranslmed.aaf6219"},{"issue":"3\u20134","key":"8584_CR343","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.cytogfr.2008.04.001","volume":"19","author":"A Ashkenazi","year":"2008","unstructured":"Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19(3\u20134):325\u201331. https:\/\/doi.org\/10.1016\/j.cytogfr.2008.04.001.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"8584_CR344","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/5517","volume":"5","author":"H Walczak","year":"1999","unstructured":"Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor\u2013related apoptosis\u2013inducing ligand in vivo. Nat Med. 1999;5(2):157\u201363. https:\/\/doi.org\/10.1038\/5517.","journal-title":"Nat Med"},{"issue":"9","key":"8584_CR345","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/cdd.2014.81","volume":"21","author":"J Lemke","year":"2014","unstructured":"Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014;21(9):1350\u201364. https:\/\/doi.org\/10.1038\/cdd.2014.81.","journal-title":"Cell Death Differ"},{"issue":"1","key":"8584_CR346","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17(1):399. https:\/\/doi.org\/10.1186\/s12885-017-3383-5.","journal-title":"BMC Cancer"},{"issue":"4","key":"8584_CR347","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1513257.","journal-title":"N Engl J Med"},{"issue":"4","key":"8584_CR348","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.cell.2007.10.037","volume":"131","author":"JE Vince","year":"2007","unstructured":"Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNF\u03b1-dependent apoptosis. Cell. 2007;131(4):682\u201393. https:\/\/doi.org\/10.1016\/j.cell.2007.10.037.","journal-title":"Cell"},{"issue":"4","key":"8584_CR349","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2007.10.030","volume":"131","author":"E Varfolomeev","year":"2007","unstructured":"Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-\u03baB activation, and TNF\u03b1-dependent apoptosis. Cell. 2007;131(4):669\u201381. https:\/\/doi.org\/10.1016\/j.cell.2007.10.030.","journal-title":"Cell"},{"key":"8584_CR350","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cyto.2016.08.035","volume":"101","author":"E Varfolomeev","year":"2018","unstructured":"Varfolomeev E, Vucic D. Intracellular regulation of TNF activity in health and disease. Cytokine. 2018;101:26\u201332. https:\/\/doi.org\/10.1016\/j.cyto.2016.08.035.","journal-title":"Cytokine"},{"issue":"2","key":"8584_CR351","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nrd3627","volume":"11","author":"S Fulda","year":"2012","unstructured":"Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109\u201324. https:\/\/doi.org\/10.1038\/nrd3627.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"8584_CR352","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.molcel.2011.06.006","volume":"43","author":"T Tenev","year":"2011","unstructured":"Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F, et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell. 2011;43(3):432\u201348. https:\/\/doi.org\/10.1016\/j.molcel.2011.06.006.","journal-title":"Mol Cell"},{"issue":"2","key":"8584_CR353","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0092-8674(03)00521-X","volume":"114","author":"O Micheau","year":"2003","unstructured":"Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181\u201390. https:\/\/doi.org\/10.1016\/S0092-8674(03)00521-X.","journal-title":"Cell"},{"issue":"10","key":"8584_CR354","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/cdd.2010.44","volume":"17","author":"BL Probst","year":"2010","unstructured":"Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-\u03b1-dependent manner. Cell Death Differ. 2010;17(10):1645\u201354. https:\/\/doi.org\/10.1038\/cdd.2010.44.","journal-title":"Cell Death Differ"},{"issue":"8","key":"8584_CR355","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrc2889","volume":"10","author":"M Gyrd-Hansen","year":"2010","unstructured":"Gyrd-Hansen M, Meier P. Iaps: from caspase inhibitors to modulators of NF-\u03baB, inflammation and cancer. Nat Rev Cancer. 2010;10(8):561\u201374. https:\/\/doi.org\/10.1038\/nrc2889.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8584_CR356","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41392-024-01769-5","volume":"9","author":"Q Zhou","year":"2024","unstructured":"Zhou Q, Meng Y, Li D, Yao L, Le J, Liu Y, et al. Ferroptosis in cancer: from molecular mechanisms to therapeutic strategies. Sig Transduct Target Ther. 2024;9(1):55. https:\/\/doi.org\/10.1038\/s41392-024-01769-5.","journal-title":"Sig Transduct Target Ther"},{"key":"8584_CR357","doi-asserted-by":"publisher","unstructured":"Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E\u2013mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol. 2020;5(43). https:\/\/doi.org\/10.1126\/sciimmunol.aax7969.","DOI":"10.1126\/sciimmunol.aax7969"},{"key":"8584_CR358","doi-asserted-by":"publisher","unstructured":"Chen H, Yang H, Guo L, Sun Q. The role of immune checkpoint inhibitors in cancer therapy: mechanism and therapeutic advances. MedComm. 2025;6(10). https:\/\/doi.org\/10.1002\/mco2.70412.","DOI":"10.1002\/mco2.70412"},{"key":"8584_CR359","doi-asserted-by":"publisher","first-page":"720748","DOI":"10.3389\/fimmu.2021.720748","volume":"12","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Consoli F, Ghidini A, Perego G, Luciani A, Mercurio P, et al. Efficacy of immune checkpoint inhibitors in rare tumours: a Systematic review. Front. Immunol. 2021;12:720748. https:\/\/doi.org\/10.3389\/fimmu.2021.720748.","journal-title":"Front. Immunol"},{"issue":"1","key":"8584_CR360","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41698-024-00570-5","volume":"8","author":"W Zhang","year":"2024","unstructured":"Zhang W, Zhu Y, Liu H, Zhang Y, Liu H, Adegboro AA, et al. Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response. NPJ Precis Onc. 2024;8(1):77. https:\/\/doi.org\/10.1038\/s41698-024-00570-5.","journal-title":"Npj Precis Onc"},{"key":"8584_CR361","doi-asserted-by":"publisher","first-page":"1396490","DOI":"10.3389\/fonc.2024.1396490","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol. 2024;14:1396490. https:\/\/doi.org\/10.3389\/fonc.2024.1396490.","journal-title":"Front Oncol"},{"issue":"16","key":"8584_CR362","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"L Maude Shannon","year":"2014","unstructured":"Maude Shannon L, Frey N, Shaw Pamela A, Aplenc R, Barrett David M, Bunin Nancy J, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1407222.","journal-title":"N Engl J Med"},{"issue":"26","key":"8584_CR363","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354. https:\/\/doi.org\/10.1056\/NEJMoa1200690.","journal-title":"N Engl J Med"},{"issue":"2","key":"8584_CR364","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG. Molecular mechanisms of drug resistance. The J Pathol. 2005;205(2):275\u201392. https:\/\/doi.org\/10.1002\/path.1706.","journal-title":"The J Pathol"},{"issue":"11","key":"8584_CR365","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. JCO. 1984;2(11):1281\u201388. https:\/\/doi.org\/10.1200\/JCO.1984.2.11.1281.","journal-title":"JCO"},{"issue":"8","key":"8584_CR366","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741\/Cancer and leukemia group B trial 9741. J Clin Oncol. 2003;21(8):1431\u201339. https:\/\/doi.org\/10.1200\/JCO.2003.09.081.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8584_CR367","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10549-017-4646-1","volume":"169","author":"L Zhang","year":"2018","unstructured":"Zhang L, Yu Q, Wu XC, Hsieh MC, Loch M, Chen VW, et al. Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I\u2013III breast cancer: ER+\/PR+, HER2- vs. triple-negative. Breast Cancer Res Treat. 2018;169(1):175\u201387. https:\/\/doi.org\/10.1007\/s10549-017-4646-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8584_CR368","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337. https:\/\/doi.org\/10.1002\/cncr.11882.","journal-title":"Cancer"},{"issue":"24","key":"8584_CR369","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","volume":"21","author":"GH Lyman","year":"2003","unstructured":"Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21(24):4524\u201331. https:\/\/doi.org\/10.1200\/JCO.2003.05.002.","journal-title":"JCO"},{"key":"8584_CR370","doi-asserted-by":"publisher","unstructured":"Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J. Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a Systematic review and meta-analysis. Oncologist. 2021;26(9):e1609\u201318. https:\/\/doi.org\/10.1002\/onco.13822.","DOI":"10.1002\/onco.13822"},{"issue":"10","key":"8584_CR371","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"ME Lacouture","year":"2006","unstructured":"Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer. 2006;6(10):803\u201312. https:\/\/doi.org\/10.1038\/nrc1970.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"8584_CR372","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1200\/JCO.2004.11.057","volume":"22","author":"R P\u00e9rez-Soler","year":"2004","unstructured":"P\u00e9rez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, et al. Determinants of tumor response and survival with erlotinib in patients with non\u2014small-Cell lung cancer. JCO. 2004;22(16):3238\u201347. https:\/\/doi.org\/10.1200\/JCO.2004.11.057.","journal-title":"JCO"},{"issue":"8","key":"8584_CR373","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","volume":"11","author":"DR Camidge","year":"2014","unstructured":"Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014;11(8):473\u201381. https:\/\/doi.org\/10.1038\/nrclinonc.2014.104.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"8584_CR374","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cllc.2024.09.006","volume":"26","author":"ND Robinson","year":"2025","unstructured":"Robinson ND, Canavan ME, Zhan PL, Udelsman BV, Pathak R, Boffa DJ, et al. Treatment patterns and clinical outcomes in patients with EGFR-Mutated non\u2013small-Cell lung cancer after progression on Osimertinib. Clin Lung Cancer. 2025;26(1):9\u201317.e3. https:\/\/doi.org\/10.1016\/j.cllc.2024.09.006.","journal-title":"Clin Lung Cancer"},{"key":"8584_CR375","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2009\/567486","volume":"2009","author":"A Harandi","year":"2009","unstructured":"Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and toxicity of anti-EGFR therapy in common cancers. J Oncol. 2009;2009:1\u201314. https:\/\/doi.org\/10.1155\/2009\/567486.","journal-title":"J Oncol"},{"issue":"2","key":"8584_CR376","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368. https:\/\/doi.org\/10.1056\/NEJMra1703481.","journal-title":"N Engl J Med"},{"issue":"2","key":"8584_CR377","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","volume":"53","author":"SQ Tang","year":"2021","unstructured":"Tang SQ, Tang LL, Mao YP, Li WF, Chen L, Zhang Y, et al. The pattern of time to onset and resolution of immune-related adverse events Caused by immune checkpoint inhibitors in cancer: a pooled analysis of 23 clinical trials and 8, 436 patients. Cancer Res Treat. 2021;53(2):339\u201354. https:\/\/doi.org\/10.4143\/crt.2020.790.","journal-title":"Cancer Res Treat"},{"key":"8584_CR378","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","volume":"54","author":"JM Michot","year":"2016","unstructured":"Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139\u201348. https:\/\/doi.org\/10.1016\/j.ejca.2015.11.016.","journal-title":"Eur J Cancer"},{"issue":"28","key":"8584_CR379","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, et al. Impact of baseline steroids on Efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-Cell lung cancer. J Clin Oncol. 2018;36(28):2872\u201378. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006.","journal-title":"JCO"},{"issue":"18","key":"8584_CR380","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124(18):3706\u201314. https:\/\/doi.org\/10.1002\/cncr.31629.","journal-title":"Cancer"},{"issue":"31","key":"8584_CR381","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1200\/JCO.24.00191","volume":"42","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, de Groot JS, Fabriek BO, Hew MN, May AM, Suijkerbuijk KPM. Corticosteroids for immune-related adverse events and checkpoint inhibitor Efficacy: analysis of six clinical trials. J Clin Oncol. 2024;42(31):3713\u201324. https:\/\/doi.org\/10.1200\/JCO.24.00191.","journal-title":"JCO"},{"issue":"2","key":"8584_CR382","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8584_CR383","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000338393","volume":"22","author":"MJ Duffy","year":"2013","unstructured":"Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Med Princ Pract. 2013;22(1):4\u201311. https:\/\/doi.org\/10.1159\/000338393.","journal-title":"Med Princ Pract"},{"issue":"5","key":"8584_CR384","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1084\/jem.103.5.653","volume":"103","author":"TT Puck","year":"1956","unstructured":"Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med. 1956;103(5):653\u201366. https:\/\/doi.org\/10.1084\/jem.103.5.653.","journal-title":"J Exp Med"},{"issue":"5","key":"8584_CR385","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NAP Franken","year":"2006","unstructured":"Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1(5):2315\u201319. https:\/\/doi.org\/10.1038\/nprot.2006.339.","journal-title":"Nat Protoc"},{"issue":"6190","key":"8584_CR386","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396\u2013401. https:\/\/doi.org\/10.1126\/science.1254257.","journal-title":"Science"},{"issue":"6282","key":"8584_CR387","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352(6282):189\u201396. https:\/\/doi.org\/10.1126\/science.aad0501.","journal-title":"Science"},{"issue":"4","key":"8584_CR388","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0106","volume":"1","author":"AC Faber","year":"2011","unstructured":"Faber AC, Corcoran RB, Ebi H, Sequist LV, Waltman BA, Chung E, et al. BIM expression in treatment-na\u00efve cancers predicts responsiveness to kinase inhibitors. Cancer DiscovCancer Discov. 2011;1(4):352\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0106.","journal-title":"Cancer DiscovCancer Discov"},{"issue":"7436","key":"8584_CR389","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nature11814","volume":"494","author":"M Das Thakur","year":"2013","unstructured":"Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque MP, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature. 2013;494(7436):251\u201355. https:\/\/doi.org\/10.1038\/nature11814.","journal-title":"Nature"},{"issue":"3","key":"8584_CR390","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1535-6108(02)00127-7","volume":"2","author":"A Letai","year":"2002","unstructured":"Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2(3):183\u201392. https:\/\/doi.org\/10.1016\/S1535-6108(02)00127-7.","journal-title":"Cancer Cell"},{"issue":"4","key":"8584_CR391","doi-asserted-by":"publisher","first-page":"336","DOI":"10.18632\/oncotarget.262","volume":"2","author":"RB Corcoran","year":"2011","unstructured":"Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget. 2011;2(4):336\u201346. https:\/\/doi.org\/10.18632\/oncotarget.262.","journal-title":"Oncotarget"},{"issue":"9","key":"8584_CR392","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/nchembio817","volume":"2","author":"JB Fitzgerald","year":"2006","unstructured":"Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol. 2006;2(9):458\u201366. https:\/\/doi.org\/10.1038\/nchembio817.","journal-title":"Nat Chem Biol"},{"issue":"11","key":"8584_CR393","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009;69(11):4894\u2013903. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3658.","journal-title":"Cancer Res"},{"key":"8584_CR394","doi-asserted-by":"publisher","unstructured":"Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci Transl Med. 2016;8(327):327ra24. https:\/\/doi.org\/10.1126\/scitranslmed.aad7842.","DOI":"10.1126\/scitranslmed.aad7842"},{"issue":"2","key":"8584_CR395","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107.","journal-title":"Nat Rev Immunol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08584-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08584-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:11:52Z","timestamp":1791241912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08584-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":395,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8584"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08584-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to partcipate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to public","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1240"}}